C.-S. Chen
CURRICULUM VITAE
Ching-Shih Chen, Ph.D.
I. General Information
Distinguished Research Fellow & Director
Institute of Biological Chemistry
Academia Sinica
Taipei, Taiwan
Tel: 886-02-2785-5696 ext. 1013
E-mail: chencs@gate.sinica.edu.tw
II. Education
Institution
University of Wisconsin – Madison
University of Wisconsin - Madison
National Taiwan University
National Taiwan University
Lucius A. Wing Chair of Cancer Research and
Therapy
Professor of Medicinal Chemistry, Internal Medicine
The Ohio State University
Columbus, OH 43210, USA
Tel: 614-688-4008
E-mail: chen.844@osu.edu
Degree
Postdoc.
Ph.D.
M.S.
B.S.
Years
1/85 – 12/86
9/80 – 1/85
9/78 – 6/80
9/74 – 6/78
Area of Study
Medicinal Chemistry
Pharmaceutical Biochemistry
Biochemistry
Agricultural Chemistry
III. Academic Appointments
The Ohio State University
April 2001 Professor of Medicinal Chemistry
Member, The Comprehensive Cancer Center and Chemistry-Biology
April 2001 Interface Training Program
June 2002 -
Professor of Internal Medicine and Urology
University of Kentucky
July 1998 – March 2001
July 1995 – June 1998
July 1995 – March 2001
Professor of Pharmaceutical Sciences
Associate Professor of Pharmaceutical Sciences
Member, Markey Cancer Center
University of Rhode Island
July 1991 – June 1995
January 1987 – June 1991
Associate Professor of Medicinal Chemistry & Pharmacognosy
Assistant Professor of Medicinal Chemistry & Pharmacognosy
III. Honors
United States
2014 -
Elected Fellow, National Academy of Inventors
2009 - 2010
Clinical trials of two drugs developed in my lab, OSU-03012 (AR12) and OSUHDAC42 (AR42), in solid and hematological malignancies at OSUCCC and in the
United Kingdom
2010 - 2012
Programmatic Review Committee, CDMRP Prostate Cancer Research Program
2007, 2008
Prostate Cancer Foundation (formerly CapCure) Research Awards for two
consecutive years
Hearst Foundation Research Award
2008
1
C.-S. Chen
2004 -
Elected Fellow, American Association for the Advancement of Science (AAAS)
2004
Winner of the V Foundation-AACR Grants in Translational Cancer Research
1994
Shannon Award, NIH
The Ohio State University
2005 - Present The Lucius A. Wing Chair of Cancer Research and Therapy, OSU Medical Center
2010
The Inaugural Innovator of the Year Award, OSU
2010
Distinguished University Scholar Award, OSU
2008
Innovation in Drug Discovery Award, College of Pharmacy, OSU
2003 - 2006
Kimberly Chair Professorship, OSU College of Pharmacy
Taiwan
2005 - 2014
Scientific Advisory Committee, Institute of Biological Chemistry, Academia Sinica,
Taiwan
2005 - 2011
Scientific Advisory Committee, National Science and Technology Program in
Biotechnology and Pharmaceuticals, Taiwan
2009- Present Honorary Chair Professor, Institute of Molecular and Cell Biology, National ChungHsin University, Taiwan
2013- Present Honorary Chair Professor, College of Medicine, National Cheng Kung University
2007- Present Adjunct Professor, College of Pharmacy, National Taiwan University
2006 - 2010
2004 - 2006
Honorary Chair Professor, Department of Biological Science and Technology, China
Medical University
Honorary Chair Professor, College of Pharmacy, Kaohsiung Medical University,
Taiwan
University of Kentucky and University of Rhode Island
2000
Outstanding Faculty Award, College of Pharmacy, University of Kentucky
1999
Outstanding Professor Award, College of Pharmacy, University of Kentucky
1992
Teacher of the Year Award, College of Pharmacy, University of Rhode Island
IV. Grant Review Panel
2010 - 2012
CDMRP Prostate Cancer Research Program, Programmatic Review Committee
2009
NCI Drug Discovery and Development P01 Special Emphasis Panel, ZCA1 RPPB-P
2009
Canadian Cancer Society Research Institute, Program project Site Visit at University of
Montreal
2004 - 2009
Chartered member, Basic Mechanism for Cancer Therapeutics (BMCT) Study Section,
NCI
2008
NCI Drug Discovery and Development P01 Special Emphasis Panel, ZCA1 RPPB-M
2006
California Breast Cancer Research Program, Pathogenesis committee
2
C.-S. Chen
2005
California Breast Cancer Research Program, Innovative Treatments/Earlier Detection
committee
2004
CDMRP Prostate Cancer Research Program CET-3 grant reviews
2004
NICDC Special Emphasis Panel to evaluate clinical center grant (P50) application
2003
CDMRP, Prostate Cancer Research Program, Clinical & Experimental Therapeutics #3,
CET-3
2003
Co-chair, NIDDK O’Brien Urology Center Grants Review
2003
NCI Special Emphasis Panel Member. FLAIR applications
2002
NCI Program Project Site Visit (P01 CA100336-01)
2002
2001
NCI Initial Review Group, Subcommittee C
NIH, NIDDK Special Emphasis Panel, RFA: Role of Hormones and Growth Factors in
Prostate Cancer
1999 -2001
California Breast Cancer Research Program, Pathogenesis Review Committee
V. Teaching Activity
Professional Pharmacy Courses
Biopharmacy II (The Ohio State University)
Physiological Chemistry and Molecular Biology II (University of Kentucky)
Basic Principles of Pharmaceutical Science: Drug Form Design (Univ. of Kentucky)
Pharmacognosy I: Basic Immunology & Biologics (University of Rhode Island)
Pharmacognosy II: Antibiotics (University of Rhode Island
Graduate-Level Courses
Graduate Seminars (The Ohio State University)
Drug Discovery and Design (two lectures; The Ohio State University)
Biocatalysis (The Ohio State University)
Natural Products Chemistry (University of Kentucky)
Graduate Seminars (University of Kentucky; Fall 1997 – Spring 1999)
Biocatalysis - Principle and Application (University of Rhode Island)
VI. Advising Activity
A. Students
University of Rhode Island (1987 – 1995)
Student/degree
Date completed
1 Shawn Harriman/M.S.
5/1990
2 Pei-Heng Lu/M.S.
5/1990
3 Yeuk-Chuen Liu/Ph.D. 5/1992
4 Joyce Li/Ph.D.
5/1995
University of Kentucky (1995 – 2001)
PhD student
Date completed
5
Pei-Jung Lu
12/1998
6
7
Ao-Lin Hsu
11/2000
Tsui-Ting Ching
11/2000
Current position
Assoc. Professor, National Taiwan Ocean University
Pharmaceutical industry, Taiwan
Current position
Professor, Institute of Clinical Medicine, National ChengKung University, Taiwan
Prof., Institute of Biochemistry, National Yang-Ming
University, Taiwan
Associate Professor, Institute of Biopharmaceutical
Sciences, National Yang-Ming University, Taiwan
3
C.-S. Chen
8
9
Xueqing Song
Amy Johnson
6/2002
6/2002
Pharmaceutical industry, US
Assistant Prof., Internal Medicine, Ohio State University
The Ohio State University (2001 – present)
PhD Student
Period
Title of Research Project
Synthetic medicinal chemistry;
2001 10 Jiuxiang Zhu
design and synthesis of PDK-1
2005
kinase inhibitors
Synthetic medicinal chemistry;
2001 11 Qiang Lu
design and synthesis of novel
2005
histone deacetylase inhibitors
12 Kuen-Feng Chen
2001 2005
Synergistic enhancement of
apoptosis induction by celecoxib
13 Ho-Pi Lin,
2001 2005
14 Chung-Wai Shiau
2001 2005
15
Jui-Wen Huang
2001 2005
16
Yang-Jeng Shaw
2001 2005
COX-2 signaling; PI 3-kinase in
Ca2+ regulation
Synthetic medicinal chemistry;
design and synthesis of Bcl-xL
binding inhibitors and -cateninablative agents
Synthetic medicinal chemistry;
design and synthesis of cyclin D1ablative agents
Synthetic medicinal chemistry;
design and synthesis of Akttargeted agents, Bcl-2 inhibitors,
and DNA methyltransferase
inhibitors
Current position
Pharmaceutical Industry,
China
Pharmaceutical Industry,
US
Attending
Physician/Assistant
Professor, National
Taiwan Univ. Hospital
Research scientist, NIH
Assistant Prof., Graduate
Institute of Pharmaceutical
Sciences, National YangMing University
Assistant Research Fellow,
Industrial Technology
Research Institute, Taiwan
Assistant Prof., Chemistry,
Tang-Kang University,
Taiwan
Assistant Prof.,
Biochemistry, National
Yang-Ming University,
Taiwan
17
Ping-Hui Tseng
2001 2006
Overcoming drug resistance in
cancer cells using a novel PDK-1
inhibitors
18
Ya-Ting Yang
2001 2006
Overcoming cisplatin resistance in
ovarian cancer cells
Taiwan FDA
Chang-Shi Chen
2002 2006
Novel nonepigentic mechanisms of
histone deacetylase inhibitors
Assistant Prof.,
Biochemistry, National
Cheng-Kung University,
Taiwan
19
20
Chi-Cheng Yang
2002 2007
21
Shu-Chiuan
Wen
2004 2008
Role of Bcl-xL and PI3-kinase in
the survival of prostate cancer cells;
mechanistic characterizations of a
novel class of androgen receptorablative agents
Novel therapeutic strategies for
breast cancer
4
Postdoc., Burnham
Institute
Postdoc., UCSD
C.-S. Chen
2004 2008
2005 2009
Novel therapeutic strategies for
lung cancer
Synthesis of Bcl-2 inhibitors and
AR-ablative agents
Transgenic prostate cancer animal
models for preclinical testing of
chemopreventive agents
22
Yu-Chieh Wang
23
Jian Yang
24
Aaron Sargeant,
DVM
2005 2009
25
Yi-Hui Ma
2005 2012
Synthesis of PKC-activating
agents
26
Shuo Wei
2005 2009
Mechanistic investigations of
ubiquitin-proteasome system
27
Po-Hsien Huang
2005 2010
Targeting Bcl-xL and AR functions
in prostate cancer
28
Su-Lin Lee
29
Hsiao-Ching
Chuang
2007 2012
2007 2012
Computer-based design of integrinlinked kinase inhibitors
Novel therapeutic strategies for
triple-negative breast cancer
30
Hany Omar
2006 2010
Novel therapeutic strategies for
hepatocellular carcinoma
31
Lisa BermanBooty, VMD
2009 2013
32
Chih-Chien
Chou
2009 2014
33
En-Chi Hsu
2009 2014
34
Wei-Ling Chang
2009 -
35
Yi-Chiu Kuo
2011 -
36
Po-Ting Lai
2011 -
37
38
39
40
Lauren Mattei,
DVM
Yu-Chou Tseng
Chun-Sheng
Fang
Sally
Henderson,
2012 2012 2013 2014 -
Transgenic prostate cancer animal
models for preclinical testing of
chemopreventive agents
Inhibition of epithelialmesenchymal transition by novel
integrin-linked kinase inhibitors
Targeting ALDH-positive
subpopulation of prostate cancer
cells by novel small-molecule
agents
Development of novel Sirt3
inducers
Cross talk between energy
restriction and epigenetic gene
regulation
Synthetic medicinal chemistry;
Development of novel AMPK
activators
Novel therapeutic strategies for
triple negative breast cancer
Cancer cachexia
Mechanistic characterization of
novel AMPK activators
Development of a novel transgenic
mouse model of pancreatic cancer
5
Postdoc., UCSD
Postdoc., Johns Hopkins
Veterinary Pathologist II,
Charles River Preclinical
Service
Henan Academy of
Agricultural Sciences,
China
Postdoc., Harvard Medical
School
Research assistant
professor; National Cheng
Kung Universitym Taiwan
Postdoc., NIH
Postdoc., OSU
Assistant professor,
College of Pharmacy,
University of Cairo
Postdoctoral Fellow,
Thomas Jefferson Cancer
Center
Postdoctoral fellow, OSU
Postdoctoral fellow, OSU
Current student
Current student
Current student
Current student
Current student
Current student
Current student
C.-S. Chen
DVM
Academia Sinica
41
Hsing-Yu Wu
2014 -
Regulation of Akt signaling in
pancreatic cancer
Current student
B. Postdoctoral Fellows
Postdoctoral fellows
Period
University of Rhode Island
Da-Ming Gou,
19901
Ph.D.
1994
19922
Ming Li, Ph.D.
1993
Title of Research Project
Current position
Asymmetric synthesis of inositol
phosphates and inositol lipids
Role of inositol lipids in Akt
activation
Pharmaceutical industry,
US
University of Kentucky
Dasheng Wang,
3
Ph.D.
Chi-Ming Chiu,
4
Ph.D.
Guanjun Cheng,
5
MD/Ph.D.
Synthetic medicinal chemist;
development of Akt inhibitors
Natural products chemist;
identification of Akt inhibitors
Biological functions of inositol
lipids in platelet activation
19962000
19971998
19981999
-
Research scientist, OSU
-
Ohio State University
6
Chin-Chung
Hung, Ph.D.
8/2002 –
8/2003
Antitumor mechanism of celecoxib
7
Ching-Ju Weng,
Ph.D.
8/2004 –
7/2005
Novel indole-3-carbinol derivatives
as potent antitumor agents
8
Yoko Kashida,
DVM/PhD
4/2005 –
8/2006
Orthotopic hepatocellular
carcinoma xenograft models
9
Hao-Chieh Chiu,
Ph.D.
11/2005 – Use of autophagy-inducing agents
7/2009
to eradicate intracellular pathogens
10
Hsiao-Ching
Yang, Ph.D.
4/2006 –
9/2006
Computer modeling-based drug
design
11
Jui-Hsiang
Hung, Ph.D.
8/2006 –
7/2008
Novel therapeutic strategies for
HCC
12
Wan-Chi Tsai,
Ph.D.
1/2007 –
8/2008
HDAC inhibitors in pancreatic
cancer
13
Navalbhai
Kapuriya, Ph.D.
6/2009 –
3/2012
Development of novel Akt-targeted
inhibitors
14
Kuen-Haur Lee,
12/2009-
AMPK as a novel therapeutic target
6
Research scientist,
Institute of Biological
Chemistry, Academia
Sinica, Taiwan
Associate Professor, China
Medical University,
Taiwan
Battelle Memorial Institute
Assistant professor,
Medical Technology,
National Taiwan
University
Assistant professor, Fu-Jen
Catholic University,
Taiwan
Assistant professor, ChaNan Pharmaceutical
University, Taiwan
Assistant professor, KaoHsiung Medical
University, Taiwan
Assistant Professor,
Saurashtra University,
India
Assistant Professor, Taipei
C.-S. Chen
Ph.D.
7/ 2012
for triple-negative breast cancer
15
Junfeng Wang,
Ph.D.
2/2010 –
2/2011
Development of novel inhibitors of
casein kinase 2
-
16
Po-Chen Chu,
Ph.D.
2/2010 -
Energy restriction-mimetic agents
in prostate cancer therapy
Assistant Professor,
National Cheng Kung
University, Taiwan
17
I-Lu Lai, Ph.D.
10/2010 -
18
Ribai Yan,
Ph.D.
19
20
21
22
Hsiao-Ching
Chuang. Ph.D.
Ming-Chen
Yang, Ph.D.
Santosh
Salunke, Ph.D.
Chia-Hsein Wu,
Ph.D.
Vinod P.
Vyavahare,
Ph.D.
Appaso Jadhav,
PhD
Hypoxia-induced EMT in prostate
cancer cells
Synthetic medicinal chemist;
4/2011synthesis of PHLPP1-targeted Akt
1/31/2015
inhibitors
7/1/2012 Cross talk between integrin-linked
kinase and LSD1
TGF signaling in pancreatic
8/2012cancer
Design and synthesis of novel anti8/2012 TB agents
9/2012 –
Design and synthesis of novel
5/31/2015 anticancer/antiviral agents
Medical University,
Taiwan
Postdoctoral fellow, OSU
Current postdoctoral
fellow
Current postdoctoral
fellow
Current postdoctoral
fellow
Current postdoctoral
fellow
Current postdoctoral
fellow
5/2013 –
4/2014
Design and synthesis of novel
anticancer agents
Pharmaceutical industry,
India
12/2014 present
Design and synthesis of novel
anticancer/antiviral agents
Current postdoctoral
fellow
Academia Sinica
Fang-Shiu Shen,
25
Ph.D.
9/1/2014
-
Current postdoctoral
fellow
Shu-Jung Yang,
Ph.D.
1/1/2015
- present
Chia-Hsein Wu,
Ph.D.
Dilip Detroja,
Ph.D.
6/1/2015
–
6/1/2015
-
Role of HDAC8 in regulating
breast cancer stem cells
Targeting IGF-IR expression as a
therapeutic strategy to prevent
colon cancer liver metastasis
Design and synthesis of novel
CREB inhibitors
Design and synthesis of novel
anticancer/antiviral agents
Period
6/2001 –
3/2003
Title of Research Project
Antitumor mechanism of celecoxib
and derivatives
Current position
23
24
26
27
28
C. Clinical Fellow
Clinical Fellows
Pat Ward, MD/Ph.D.
Yen-Shen Lu,
MD/Ph.D.
12/2005 –
12/2006
HDAC inhibitors in HCC therapy
Jaw-Shiun Tsai,
MD/Ph.D.
2/2006 –
8/2006
Regulation of inflammatory
cytokine production by smallmolecule agents
7
Current postdoctoral
fellow
Current postdoctoral
fellow
Current postdoctoral
fellow
Private practice
Attending physician/
Assistant prof., National
Taiwan University
Hospital
Attending physician,
National Taiwan
University Hospital
C.-S. Chen
Yu-Lin Lin, MD/PhD
2/2007 –
1/2008
Novel therapeutic strategies for
pancreatic cancer
Li-Yuan Bai,
MD/PhD
2/2008 –
6/2010
Novel therapeutic strategies for
CLL
Hsiang-Yu Lin,
MD/PhD
7/2010 –
6/2011
Energy restriction and DNA
methylation in prostate cancer
Lawrence Shirley,
MD
9/2012
Development of novel therapeutic
strategies for pancreatic cancer
Peng-Chan Lin,
MD/PhD
10/2012
Role of YB-1-IGF-IR signaling in
liver metastasis of colorectal cancer
cells
D. Visiting Professors
Visiting Professor
Period
Title of Research Project
Pei-Jung Lu, Ph.D.
6/2006 –
9/2006
Development of kinase inhibitors
Geen-Dong Chang,
Ph.D.
7/2007 –
6/2008
Autophagy
Jih-Hwa Guh, Ph.D.
7/2008 –
6/2009
Development of small-molecule
anti-cytokine agents and novel
AMPK activators
Hsiao-Ching Yang,
Ph.D.
7/2011 –
9/2011
Lin Zhang, PhD
6/2013 –
5/2014
Jianyun Liu, PhD
3/2014 –
2/2015
Computer modeling-based drug
design
Mechanistic characterization of
anticancer mechanisms of natural
products
Mechanistic characterization of
anticancer mechanisms of natural
products
E. Visiting Scholars
Visiting Scholars
Period
Chen-Hsun Tsai
6/ 2006 – 5/2009
Chun-Han Chen
8/2008 – 7/2010
Mei-Chuan Chen
8/2008 – 7/2010
Attending physician,
National Taiwan
University Hospital
Assistant Professor, China
Medical University,
Taiwan
Attending physician/
McKay Memorial
Hospital, Taiwan
Clinical fellow, surgical
oncology, OSU hospital
Attending physician,
Medical Oncology,
National Cheng Kung
University Hospital
Current Position
Professor, Institute of
Clinical Medicine,
National Cheng-Kung
University, Taiwan
Professor and Director,
Institute of Biochemical
Sciences, National Taiwan
University
Dean and Professor,
School of Pharmacy,
National Taiwan
University
Assistant Professor, FuJen Catholic University
Associate Professor,
Zhejiang University, PRC
Associate Professor,
Soochow University, PRC
Title of Research Project
Development of EGFR/Src signaling
inhibitors
Visiting Ph.D. student from Department of
Pharmacology, NTU; energy restriction and
epigenetics; Postdoctoral fellow, Genomic
Research Center, Academia Sinica, Taiwan
Visiting Ph.D. student from Department of
Pharmacology, NTU; drug-induced
8
C.-S. Chen
Yu-Chen Hou
2/2009 – 1/2010
Yi-Chiu Kuo
8/2010 – 1/2011
Yu-Chou Tseng
5/2011 – 5/2012
Yo-Ting Tsai
6/2011 – 5/2012
Han-Li Huang
8/2012 -
Huang-Ju Tu
8/2012 -
Min-Wu Chao
8/2012 -
Chun-Sheng Fang
8/2012 – 5/2013
Hao-Yu Hsieh
4/1/2015 -
proteasomal degradation of topoisomerase
II in HCC cells.
Assistant Professor, Taipei Medical
University, Taiwan
Visiting Ph.D. student from Department of
Human Nutrition, Taipei Medical
University; novel therapeutic strategies for
triple-negative breast cancer
Energy restriction and epigenetics
Targeting ALDH-positive pancreatic cancer
cells by small-molecule agents
Targeting ALDH-positive pancreatic cancer
cells by small-molecule agents
Visiting Ph.D. student from Department of
Pharmacology, NTU; Mucin-1 signaling in
pancreatic cancer
Visiting Ph.D. student from Department of
Pharmacology, NTU; Role of AMPK in
regulating colon cancer metastasis
Visiting Ph.D. student from Department of
Pharmacology, NTU; Role of Class I HDAC
isozymes in regulating Notch signaling
Development of novel host-targeted agents
against intracellular bacteria
Design and synthesis of novel anti-MRSA
agents
VII. Research and/or Creative Productivity
Publications (h-index = 57 per Google Scholar search as of December 2013)
2015
1.
Y.-C. Tseng, S. K. Kulp, I-L. Lai, E.-C. Hsu, W. A. He, D. E. Frankhouser, P. S. Yan, M. Bloomston,
G. B. Lesinski, G. Marcucci, D. C. Guttridge, T. Bekaii-Saab, and C.-S. Chen (2015) “Preclinical
investigation of the novel histone deacetylase inhibitor AR-42 in the treatment of cancer-induced
cachexia” J. Natl. Cancer Inst., provisionally accepted
2.
C.-C. Chou, H.-C. Chuang, S. B. Salunke, S. K. Kulp, and C.-S. Chen (2015) “A novel HIF-1αintegrin-linked kinase regulatory loop that facilitates hypoxia-induced HIF-1 expression and
epithelial-mesenchymal transition in cancer cells” Oncotarget, 6, 8271-85
3.
R. Yan, H.-C. Chuang, N. Kapuriya, C.-C. Chou, P.-T. Lai, H.-W. Chang, C.-N. Yang, S. K. Kulp,
and C.-S. Chen (2015) “Exploitation of the Ability of -Tocopherol to Facilitate Membrane Colocalization of Akt and PHLPP1 to Develop PHLPP1-Targeted Akt Inhibitors” J. Med. Chem., 58,
2290-8
4.
E.-C. Hsu, S. K. Kulp, H.-L. Huang, H.-J. Tu, M.-W. Chao, Y.-C. Tseng, M.-C. Yang, S. B.
Salunke, N. J. Sullivan, W.-C. Chen, J. Zhang, C.-M. Teng, W.-M. Fu, D. Sun, M. S. Wicha, C. L.
Shapiro, and C.-S. Chen (2015) “Integrin-linked kinase as a novel molecular switch of the IL-6NF-κB signaling loop in breast cancer” Oncogene, revised manuscript under review
5.
S. B. Salunke, A. K. Azad, N. P. Kapuriya, J.-M. Balada-Llasat, P. Pancholi, L. S. Schlesinger, and
C.-S. Chen (2015) “Design and Synthesis of Novel Anti-tuberculosis Agents from the Celecoxib
Pharmacophore” Bioorg. Med. Chem, 23, 1935-1943
6.
P.-C. Chu, M.-C. Yang, S. K. Kulp, S. B. Salunke, Y.-S. Shan, C.-T. Lee, M.-D. Lai, L. A. Shirley,
9
C.-S. Chen
7.
8.
9.
10.
11.
12.
T. Bekaii-Saab, and C.-S. Chen (2015) “Regulation of Oncogenic KRAS Signaling via a Novel
KRAS-ILK-hnRNPA1 Regulatory Loop in Pancreatic Cancer Cells” Oncogene, under revision
E.-C. Hsu, S. K. Kulp, H.-L. Huang, H.-J. Tu, S. B. Salunke, N. J. Sullivan, D. Sun, M. S. Wicha,
C. L. Shapiro, and C.-S. Chen (2015) “ILK is Responsible for -Secretase Integrity in Caveolae to
Regulate Notch1 Activation in Breast Cancer Cells” Neoplasia, revised manuscript under review
E. M. E. Dokla, C.-S. Fang, P.-T. Lai, S. K. Kulp, N. S. M. Ismail, R. A.T. Serya, K. A. M.
Abouzid, and Ching-Shih Chen (2015) “Development of Potent Adenosine MonophosphateActivated Protein Kinase Activators” under review
R, Mani, Y. Mao, F. W. Frissora, C.-L. Chiang, J. Wang, Y. Zhao, Y. Wu, B. Yu, R. Yan, X. Mo,
L. Yu, J. Flynn, J. Jones, L. Andritsos, S. Baskar, C. Rader, M. A. Phelps, C.-S. Chen, R. J. Lee, J.
C. Byrd, L. J. Lee, N. Muthusamy (2015) “Tumor antigen ROR1 targeted drug delivery mediated
selective leukemic but not normal B-cell cytotoxicity in chronic lymphocytic leukemia” Leukemia
29, 346-355
R. L. Plews, A. M. Yusof, C. Wang, M. Saji, X. Zhang, C.-S. Chen, M. D. Ringel, J. E. Phay “A
Novel Dual AMPK Activator/mTOR Inhibitor Inhibits Thyroid Cancer Cell Growth” J. Clin.
Endocrinol. Metab., accepted for publication 2015 Feb 24:jc20141777. [Epub ahead of print]
T.-M. Liu, Y. Ling, J.A. Woyach, K. Beckwith, Y.Y. Yeh, E. Hertlein, Z. Zhang, A. Lehman, F.
Awan, J.A. Jones, L.A. Andritsos, K. Maddocks, J. MacMurray, S.B. Salunke, C.-S. Chen, M.A.
Phelps, J.C. Byrd, A.J. Johnson (2015) “OSU-T315: a novel targeted therapeutic that antagonizes
AKT membrane localization and activation of chronic lymphocytic leukemia cells” Blood 125,
284-295
L.D. Berman-Booty, J.M. Thomas-Ahner, B. Bolon, M.J. Oglesbee, S.K. Clinton, S.K. Kulp, C.-S.
Chen, K. M. Perle (2015) “Extra-prostatic Transgene-associated Neoplastic Lesions in Transgenic
Adenocarcinoma of the Mouse Prostate (TRAMP) Mice” Toxicol. Pathol. 43(2), 186-97
2014
13. C.-C. Chou, K.-H. Lee, I-L. Lai, D. Wang, S. K. Kulp, C. L. Shapiro, and C.-S. Chen (2014)
“Novel Function of AMPK in Reversing the Mesenchymal Phenotype of Cancer Cells by Targeting
the Akt-MDM2-Foxo3a Signaling Axis” Cancer Res. 74, 4783-4795
14. I.-L. Lai, C.-C. Chou, P-T. Lai, L. A. Shorley, R. Yan, M. Bloomston, S. K. Kulp, T. Beckaii-Saab,
and C.-S. Chen (2014) “Targeting the Warburg effect with a novel glucose transporter inhibitor to
overcome gemcitabine resistance in pancreatic cancer cells” Carcinogenesis, 35, 2203-2213
15. C.-C. Chiu, S. Salunke, S. K. Kulp, and C.-S. Chen (2014) “Prospects on strategies for
therapeutically targeting oncogenic regulatory factors by small-molecule agents” J. Cell. Biochem.
115, 611-624
16. H.-C. Chuang, C.-C. Chou, S. K. Kulp, C.-S. Chen (2014) “AMPK as a potential anticancer target friend or foe?” Curr. Pharm. Des. 20, 2607-1618
17. J.-H. Lo, S. K. Kulp, C.-S. Chen, and H.-C. Chiu (2014) “ “Sensitization of Intracellular Salmonella
enterica Serovar Typhimurium to Aminoglycosides In Vitro and In Vivo by a Host-Targeted
Antimicrobial Agent” Antimicrob. Agents Chemother. 58, 7375-7382
18. F.T. Awan, J. Jones, L. Andritsos, K. Maddocks, C.-H. Wu, C.-S. Chen, A. Lehman, X. Zhang, R.
Lapalombella, J.C. Byrd (2014) “PKC-β as a therapeutic target in CLL: PKC inhibitor AEB071
demonstrates preclinical activity in CLL” Blood 124, 1481-1491
19. Y. Mao, J. Wang, Y. Zhao, R. Yan, H. Li, C.-S. Chen, R.J. Lee, J.C. Byrd, L.J. Lee, N.
Muthusamy, M.A. Phelps (2014) “Quantification of OSU-2S, a novel derivative of FTY720, in
mouse plasma by liquid chromatography-tandem mass spectrometry” J Pharm Biomed Anal.
10
C.-S. Chen
20.
21.
22.
23.
24.
98:160-5
J.-S. Tsai, L.-M. Chuang, C.-S. Chen, C.-J. Liang, C.-Y. Chen, and C.-Y. Chen (2014)
“Troglitazone and Δ2Troglitazone enhance adiponectin expression in monocytes/macrophages
through the AMP-activated protein kinase pathway” Mediators Inflamm. 2014 Article ID 726068;
doi: 10.1155/2014/726068
P. J. Hensley, A. Desiniotis, C. Wang, A. Stromberg, C.-S. Chen, N. Kyprianou (2014) “Novel
pharmacological targeting of tight junctions and focal adhesions in prostate cancer cells” PLoS
ONE 9, e86238
C.-H. Chen, M.-C. Chen, J.-C. Wang, A.-C. Tsai, C.-S. Chen, J.-P. Liou, S.-L. Pan, and C.-M.
Teng (2014) “Synergistic interaction between the HDAC inhibitor, MPT0E028, and sorafenib in
liver cancer cells in vitro and in vivo” Clin. Cancer Res. 20, 1274-1287
F.-L. Liu, J.-L. Hsu, Y.-J. Lee, Y.-S. Dong, F.-L. Kung, C.-S. Chen, J.-H. Guh (2014)
“Calanquinone A induces anti-glioblastoma activity through glutathione-involved DNA damage
and AMPK activation” Eur J Pharmacol. 730:90-101
Y. Mao, J. Wang, Y. Zhao, Y. Wu, K.J. Kwak, C.-S. Chen, J.C. Byrd, R.J. Lee, M.A. Phelps, L.J.
Lee, N. Muthusamy N (2014) “A novel liposomal formulation of FTY720 (fingolimod) for
promising enhanced targeted delivery” Nanomedicine 10, 393-400
2013
25. P.-H. Huang, H.-C. Chuang, C.-C. Chou, H. Wang, S.-L. Lee, H.-C. Yang, H.-C. Chiu, N. Kapuriya,
D. Wang, S. K. Kulp, and C.-S. Chen (2013) “Vitamin E Facilitates the Inactivation of the
Kinase Akt by the Phosphatase PHLPP1” Science Signaling 6 (267), ra19
26. S.-L. Lee, C.-C. Chou, H.-C. Chuang, E.-C. Hsu, P.-C. Chiu, S. K. Kulp, J. C. Byrd, and C.-S. Chen
(2013) “Functional role of mTORC2 versus integrin-linked kinase in mediating Ser473-Akt
phosphorylation in PTEN-negative prostate and breast cancer cell lines” PLoS One 8, e67149)
27. L. D. Berman-Booty, P.-C. Chu, J. M. Thomas-Ahner, B. Bolon, D. Wang, T. Yang, S. K. Clinton,
S. K. Kulp, C.-S. Chen (2013) “Suppression of Prostate Epithelial Proliferation and Intraprostatic
Pro-Growth Signaling in Transgenic Mice by a New Energy Restriction-Mimetic Agent” Cancer
Prev. Res. 6, 232-241
28.
P.-C. Chu, S. K. Kulp, and C.-S. Chen (2013) “Insulin-like growth factor-I receptor is suppressed
through transcriptional repression and mRNA destabilization by a novel energy restriction-mimetic
agent” Carcinogenesis 34, 2694-2705
29.
S. S. Bums, E. M. Akhmametyeva, J. L. Oblinger, M. L. Bush, J. Huang, V. Senner, C.-S. Chen, A.
Jacob, D. B. Welling, L.-S. Chang (2013) “Histone Deacetylase Inhibitor AR-42 Differentially
Affects Cell-cycle Transit in Meningeal and Meningioma Cells, Potently Inhibiting NF2-Deficient
Meningioma Growth” Cancer Res 73, 792-803
Y. Ma, S. K. McCarty, N. P. Kapuriya, V. J. Brendel, C. Wang, X. Zhang, D. Jarjoura, M. Saji, C.S. Chen, and M. D. Ringel (2013) “Development of p21 activated kinase-targeted multikinase
inhibitors that inhibit thyroid cancer cell migration” J. Clin. Endocrinol. Metab., 98, E1314-E1322
S.-Y. Lee, Z. Huang, T.-H. Kang,R. S. Soong, J. Knoff, E. Axenfeld, C. Wang, R. D. Ronald, C.-S.
Chen, C.-F. Hung, T.-C. Wu (2013) “Histone deacetylase inhibitor AR-42 enhances E7-specific
CD8(+) T cell-mediated antitumor immunity induced by therapeutic HPV DNA vaccination” J.
Mol. Med. 91, 122-131
30.
31.
32.
M.-C. Yen, T.-Y. Weng, Y.-L. Chen, C.-C. Lin, C.-Y. Chen, C.-Y. Wang, H.-L. Chao, C.-S. Chen,
M.-D. Lai (2013) “An HDAC inhibitor enhances cancer therapeutic efficiency of RNA polymerase
III promoter-driven IDO shRNA” Cancer Gene Ther. 20, 351-357
11
C.-S. Chen
33.
Y.-L. Yang, P.-H. Huang, H-C. Chiu, S. K. Kulp, C.-S. Chen, C.-J. Kuo, H.-D. Chen, C.-S. Chen
(2013) “Histone deacetylase inhibitor AR42 regulates telomerase activity in human glioma cells via
an Akt-dependent mechanism” Biochem. Biophys. Res. Commun. 435, 107-112
34.
S.-H. Chan, W.-J. Leu, L-C. Hsu, H.-S. Chang, T.-L. Hwang, I.-S. Chen, C.-S. Chen, J.-H. Guh
(2013) “Reevesioside F induces potent and efficient anti-proliferative and apoptotic activities
through Na⁺ /K⁺ -ATPase α3 subunit-involved mitochondrial stress and amplification of caspase
cascades” Biochem. Pharmacol. 86,1564-1575
35.
P. Neviani, J.G. Harb, J.J. Oaks, R. Santhanam, C.J. Walker, J.J. Ellis, G. Ferenchak, A.M.
Dorrance, C.A. Paisie, A.M. Eiring, Y. Ma, H.C. Mao, B. Zhang, M. Wunderlich, P.C. May, C.
Sun, S.A. Saddoughi, J. Bielawski, W. Blum, R.B. Klisovic, J.A. Solt, J.C. Byrd, S. Volinia, J.
Cortes, C.S. Huettner, S. Koschmieder, T.L. Holyoake, S. Devine, M.A. Caligiuri, C.M. Croce, R.
Garzon, B. Ogretmen, R.B. Arlinghaus , C.-S. Chen, R. Bittman, P. Hokland, D.C. Roy, D.
Milojkovic, J. Apperley, J.M. Goldman, A. Reid , J.C. Mulloy, R. Bhatia, G. Marcucci, D. Perrotti
(2013) “PP2A-activating drugs selectively eradicate TKI-resistant chronic myeloid leukemic stem
cells” J. Clin. Invest. 123, 4144-4157
2012
36. D. Wang, P.-C. Chu, C.N. Yang, R. Yan, Y.-C. Chung, S. K. Kulp, and C.-S. Chen (2012)
“Development of a Novel Class of Glucose Transporter Inhibitors” J. Med. Chem. 55, 3827-3836
37. M.-J. Lai, H.-L. Huang, S.-L. Pan, Y.-M. Liu, C.-Y. Peng, H.-Y. Lee, T.-K. Yeh, P.-H. Huang, C.M. Teng, C.-S. Chen, H.-Y. Chuang, and J.-P. Liou (2012) “Synthesis and Biological Evaluation of
1-Arylsulfonyl-5-(N-hydroxyacrylamide)indoles as Potent Histone Deacetylase Inhibitors with
Antitumor Activity in vivo” J. Med. Chem. 55, 3777-91
38. P.-C. Chu, H.-C. Chuang, S. K. Kulp, and C,-S. Chen (2012) “The mRNA-Stabilizing Factor HuR
protein Is Targeted by -TrCP protein for Degradation in response to Glycolysis Inhibition” J. Biol.
Chem. 287, 43639-50
39. S. Wei, P.-C. Chu, H.-C. Chuang, W.-C. Hung, S. K. Kulp, and C.-S Chen (2012) “Targeting the
oncogenic E3 ligase Skp2 in prostate and breast cancer cells with a novel energy restrictionmimetic agent” PLoS One, 7, e47298
40. H.-C. Chuang, N. Kapuriya, S. K. Kulp, C.-S. Chen, and C. L. Shapiro (2012) “Differential antiproliferative activities of poly(ADP-ribose)polymerase (PARP) inhibitors in triple-negative breast
cancer cells” Breast Cancer Res. Treat. 134, 649-659
41. H.-Y. Lin, Y.-C. Kuo, Y.-I. Weng, I.-L. Lai, T. H.-M. Huang, S.-P. Lin, D.-M. Niu, and C.-S. Chen
(2012) “Activation of silenced tumor suppressor genes in prostate cancer cells by a novel energy
restriction-mimetic agent” Prostate 72, 1767-1778
42. H.-C. Chiu, S.-L. Lee, N. Kapuriya, D. Wang, Y.-R. Chen, S.-L. Yu, S. K. Kulp, L.-J. Teng, and
C.-S. Chen (2012) “Development of novel antibacterial agents against methicillin-resistant
Staphylococcus aureus” Bioorg. Med. Chem. 20, 4653-4660
43. L. D. Berman-Booty, A. M. Sargeant, T. J. Rosol, R. C. Rengel, S. K. Clinton, C.-S. Chen, S. K.
Kulp (2012) “A review of the existing grading schemes and a proposal for a modified grading
scheme for prostatic lesions in TRAMP mice” Toxicol. Pathol. 40, 5-17
44. N. Bholi, M. Freilino, S. Joyce, M. Sen, S. Thomas, A. Sahu, A. Cassell, C.-S. Chen, and J.
Grandis (2012) “Anti-tumor mechanisms of targeting the PDK1 pathway in head and neck cancer”
Mol. Cancer Ther. 11, 1236-1246
45. R. Lapalombella, Y.-Y. Yeh, L. Wang,.A. Ramanunni, S. Rafiq, S. Jha, J. Staubli, D. M. Lucas, R.
Mani, S. E.M. Herman, A. J. Johnson, A. Lozanski, L. Andritsos, J. Jones, J. M. Flynn, B. Lannutti,
P. Thompson, P. Algate, S. Stromatt, D. Jarjoura, X. Mo, D. Wang, C.-S. Chen, G. Lozanski, N. A.
Heerema, S. Tridandapani, M. A. Freitas, N. Muthusamy, and J. C. Byrd (2012) “Tetraspanin
12
C.-S. Chen
46.
47.
48.
49.
50.
51.
CD37 Directly Mediates Transduction of Survival and Apoptotic Signals” Cancer Cell 21, 694-708
L. Booth, N. Cruickshanks, T. Ridder, C.-S. Chen, S. Grant, P. Dent (2012) “OSU-03012 interacts
with lapatinib to kill brain cancer cells” Cancer Biol. Ther. 13, 1501-11
L. Booth, S. C. Cazanave, H. A. Hamed, A. Yacoub, B. Ogretmen, C.-S. Chen, S. Grant, P. Dent
(2012) “OSU-03012 suppresses GRP78/BiP expression that causes PERK-dependent increases in
tumor cell killing” Cancer Biol. Ther.13, 224-36
J.-L., Hsu, Y.-F. Ho, T.-K. Li, C.-S. Chen, L.-C. Hsu, J.-H. Guh (2012) “Rottlerin potentiates
camptothecin-induced cytotoxicity in human hormone refractory prostate cancers through increased
formation and stabilization of topoisomerase I-DNA cleavage complexes in a PKCδ-independent
pathway” Biochem. Pharmacol. 84, 59-67
J.-L. Hsu, P.-K. Leong, Y.-F. Ho, L.-C. Hsu, P.-H. Lu, C.-S. Chen, J.-H. Guh (2012) “Pim-1
knockdown potentiates paclitaxel-induced apoptosis in human hormone-refractory prostate cancers
through inhibition of NHEJ DNA repair” Cancer Lett. 319, 214-22
J.-M. Shieh, T.-T. Wei, Y.-A. Tang, S.-M. Huang, W.-L. Wen, M.-Y. Chen, H.-C. Cheng , S. B.
Salunke, C.-S. Chen, P. Lin, C.-T. Chen, Y.-C. Wang (2012) “Mitochondrial apoptosis and FAK
signaling disruption by a novel histone deacetylase inhibitor, HTPB, in antitumor and antimetastatic
mouse models” PLoS One 7, e30240
A. Jacob, J. Oblinger, M. L. Bush, V. Brendel, G. Santarelli, A. R. Chaudhury, S. K. Kulp, K. M.
La Perle, C.-S. Chen, L. S. Chang, D. B. Welling (2012) “Preclinical validation of AR42, a novel
histone deacetylase inhibitor, as treatment for vestibular schwannomas” Laryngoscope 122, 174-89
2011
52. M.-C. Chen, C.-H. Chen, H.-C. Chuang, S. K. Kulp, C.-M. Teng, and C.-S. Chen (2011) “Novel
mechanism by which histone deacetylase inhibitors facilitate topoisomerase II degradation in
hepatocellular carcinoma cells” Hepatology, 53, 148-159
53. H. A. Omar, Y. C.-C. Chou, L. Berman-Booty, Y. Ma, J.-H. Hung, S. K. Kulp. T. Kogure, T. Patel,
D. Wang, N. Muthsuamy, J. C. Byrd, and C.-S. Chen (2011) “Antitumor effects of OSU-2S, a nonimmunosuppressive analogue of FTY720, in hepatocellular carcinoma” Hepatology, 53, 1943-1958
54. C.H. Chen, P.-H. Huang, P.-C. Chu, M.-C. Chen, C.-C. Chou, D. Wang, S. K. Kulp, C.-M. Teng,
and C.-S. Chen (2011) “Energy restriction-mimetic agents induce apoptosis in prostate cancer cells
in part through epigenetic activation of KLF6 tumor suppressor gene expression” J. Biol. Chem.
286, 9968-9976
55. P.-H. Huang, C.-H. Chen, C.-C. Chou, A. M. Sargeant, S. K. Kulp. C.-M. Teng, J. C. Byrd, and C.S. Chen (2011) “Histone deacetylase inhibitors stimulate histone H3 lysine 4 methylation, in part,
via transcriptional repression of histone H3 lysine 4 demethylases” Mol. Pharmacol., 79. 197-206
56. S.-L. Lee, E.-C. Hsu, C.-C. Chou, H.-C. Chuang, L.-Y. Bai, S. K. Kulp, and C.-S. Chen (2011)
“Identification and characterization of a novel integrin-linked kinase inhibitor” J. Med. Chem., 54,
6364-74
57. K.-H. Lee, E.-C. Hsu, J.-H. Guh, H.-C. Yang, D. Wang, S.K. Kulp, C. L. Shapiro, and C.-S. Chen
(2011) “Targeting energy metabolism and oncogenic signaling pathways in triple-negative breast
cancer by a novel AMPK activator” J. Biol. Chem., 286, 39247-39258
58. P.-H. Huang, C. Plass, C.-S. Chen (2011) “Effects of histone deacetylase inhibitors on modulating
H3K4 methylation marks – A novel cross-talk mechanism between histone-modifying enzymes”
Mol. Cell. Pharmacol. 3, 39-43
59. B. Wang, P.-H. Huang, C.-S. Chen, and C. J. Forsyth (2011) “Total Syntheses of the Histone
Deacetylase Inhibitors Largazole and 2-epi-Largazole: Application of N-Heterocyclic Carbene
Mediated Acylations in Complex Molecule Synthesis” J. Org. Chem. 76, 1140-1150
13
C.-S. Chen
60.
61.
62.
63.
64.
65.
66.
67.
68.
T.-T, Ching, W.-C. Chiang, C.-S. Chen, and A.-L. Hsu (2011) “Celecoxib extends C. elegans
lifespan via inhibition of insulin-like signaling but not cyclooxygenase-2 activity” Aging Cell 10,
506-519
N. K. Thudi, S. T. Shu, C. K. Martin, L. G. Lanigan, M. V. P. Nadella, A, V. Bokhoven, J. L.
Werbeck, J. K. Simmons, S. Murahari, W. C. Kisseberth, M. Breen, C. Williams, C.-S. Chen, L. K.
McCauley, E. T. Keller, and T. J. Rosol (2011) “Development of a brain metastatic canine prostate
cancer cell line” Prostate, 71, 1251-1263
B. Zimmerman, A. Sargeant, K. Landes, S. A. Fernandez, C.-S. Chen, M. D. Lairmore (2011)
“Efficacy of novel histone deacetylase inhibitor, AR42, in a mouse model of, human Tlymphotropic virus type 1 adult T cell lymphoma” Leuk. Res. 35, 1491-1497
M. L. Bush, J. Oblinger, V. Brendel, G. Santarelli, J. Huang, E. M. Akhmametyeva, S. S. Burns, J.
Wheeler, J. Davis, C. W. Yates, A. R. Chaudhury, S. Kulp. C.-S. Chen, L.-S. Chang, D. B. Welling,
A. Jacob (2011) “AR42, a novel histone deacetylase inhibitor, as a potential therapy for vestibular
schwannomas and meningiomas” Neuro. Oncol. 13, 983-99
Y.-S. Lin, A. Y. Shaw, S.-G. Wang, C.-C. Hsu, I-W. Teng, M.-J. Tseng, T. H.-M. Huang, C.-S.
Chen, Y.-W. Leu, and S.-H. Hsiao (2011) “Identification of novel DNA methylation inhibitors via
a two-component reporter gene system” J. Biomed Sci 18, 3
S. Zhang, A. Suvannasankha, C. D. Crean, V. L. White, C.-S. Chen, S. S. Farag (2011) “The novel
histone deacetylase inhibitor, AR42, inhibits gp130/Stat3 pathway and induces apoptosis and cell
cycle arrest in multiple myeloma cells”, Int. J. Cancer, 129, 204-213
L. Alinari, E. Mahoney, J. Patton, X. Zhang, L. Huynh, C. T. Earl, R. Mani, Y. Mao, B. Yu, C.
Quinion, W. H. Towns, C.-S. Chen, D. M. Goldenberg, K. A. Blum, J. C. Byrd, N. Muthusamy, M.
Praetorius-Ibba, R. A. Baiocchi, (2011) “FTY720 increases CD74 expression and sensitizes mantle
cell lymphoma cells to milatuzumab-mediated cell death” Blood, 118, 6893-6903
C. C. Hofmeister, X. Yang, F. Pichiorri, P. Chen, D. M. Rozewski, A. J. Johnson, S. Lee, Z. Liu,
C. L. Garr, E. M. Hade, J. Ji, L. J. Schaaf, D. M. Jr. Benson, E. H. Kraut, W. J. Hicks, K. K. Chan,
C.-S. Chen, S. S. Farag, M. R. Grever, J. C. Byrd, M. A. Phelps (2011) “Phase I Trial of
Lenalidomide and CCI-779 in Patients With Relapsed Multiple Myeloma: Evidence for
Lenalidomide-CCI-779 Interaction via P-Glycoprotein” Journal of Clinical Oncology 29, 34273434
L.-Y. Bai, Y. Ma, S. K. Kulp, S.-H. Wang, C.-F. Chiu, F. Frissora, R. Mani, X. Mo, D. Jarjoura, J.
C. Byrd, C.-S. Chen, N. Muthusamy (2011) ”OSU-DY7, a novel D-tyrosinol derivative, mediates
cytotoxicity in chronic lymphocytic leukaemia and Burkitt lymphoma through p38 mitogenactivated protein kinase pathway” British Journal of Haematology 153, 623-633
2010
69. S. Wei, S. K. Kulp, C.-S. Chen (2010) “Energy Restriction as an Antitumor Target of
Thiazolidinediones” J. Biol. Chem. 285, 9780-9791 (citations: 44)
70. J.-H. Guh, W.-L. Chang, J. Yang, S.-L. Lee, S. Wei, D. Wang, S. K. Kulp, and C.-S. Chen (2010)
“Development of novel adenosine monophosphate-activated protein kinase activators” J. Med.
Chem. 53, 2552-2561
71. T.-Y. Lin, J. Fenger, S. Murahari, M.D. Bear, S. K. Kulp, D. Wang, C.-S. Chen, W. C. Kisseberth,
and C. A. London (2010) “AR-42, a novel HDAC inhibitor, exhibits biologic activity against
malignant mast cell lines via down-regulation of constitutively activated Kit” Blood 115, 42174225
72. J.-R. Weng, H. A. Omar, S. K. Kulp, and C.-S. Chen (2010) “Pharmacological exploitation of
indole-3-carbinol to develop potent antitumor agents” Mini Rev Med Chem, (invited review) 10,
398-404
14
C.-S. Chen
73.
74.
75.
76.
77.
78.
79.
80.
81.
M.-D. Lai, C.-S. Chen, C.-R. Yang, S.-Y. Yuan, J.-J. Tsai, C.-F. Tu, C.-C. Wang, M.-C. Yen, and
C.-C. Lin (2010) “An HDAC inhibitor enhances the antitumor activity of a CMV promoter-driven
DNA vaccine” Cancer Gene Ther 17, 203-211
H. A. Omar, L. Berman-Booty, S. K. Kulp, and C.-S. Chen (2010) “Energy restriction as an
antitumor target” Future Oncol., 6, 1675-1679
Q. Liu, L. Alinari, C.-S. Chen, F. Yan, J. T. Dalton, R. Lapalombella, X. Zhang, R. Mani, T. Lin, J.
C. Byrd, R. A. Baiocchi, and N. Muthusamy (2010) “FTY720 shows promising in vitro and in vivo
preclinical activity by downmodulating cyclin D1 and phospho-Akt in mantle cell lymphoma”
Clin. Cancer Res. 16, 3182-3192
D. M. Lucas, L. Alinari, D. A. West, M. E. Davis, R. B. Edwards, A. J. Johnson, K. A. Blum, C. C.
Hofmeister, M. A. Freitas, M. R. Parthun, D. Wang, Amy Lehman, X. Zhang, D. Jarjoura, S. K.
Kulp, C. M. Croce, M. R. Grever, C.-S. Chen, R. A. Baiocchi., J. C. Byrd (2010) “The novel
deacetylase inhibitor AR-42 demonstrates pre-clinical activity in B-Cell malignancies in vitro and
in vivo” PLoS ONE 5, e10941
Y. A. Tang, W.-L. Wen, J.-W. Chang, T.-T. Wei, Y.-H. C. Tan, S. Salunke, C.-T. Chen, C.-S.
Chen, and Y.-C. Wang (2010) “A novel histone deacetylase inhibitor exhibits antitumor activity
via apoptosis induction, F-actin disruption and gene acetylation in lung cancer” PLoS One 5,
e12417
R. Lapalombella, L. Andritsos, Q. Liu, S. E. May, R. Browning, L. V. Pham, K. A. Blum, W.
Blum, A. Ramanunni, C. A. Raymond, L. L. Smith, A. Lehman, X. Mo, D. Jarjoura, C.-S. Chen, R.
Jr. Ford, C. Rader, N. Muthusamy, A. J. Johnson, J. C. Byrd (2010) ”Lenalidomide treatment
promotes CD154 expression on CLL cells and enhances production of antibodies by normal B Cells
through a PI3-kinase dependent pathway” Blood 115, 2619-2629
H. A. Hamed, A. Yacoub, M. A. Park, P. Eulitt, D. Sarkar, I. P. Dimitrie, C.-S. Chen, S. Grant, D.
T. Curiel, P. B. Fisher, P. Dent (2010) “OSU-03012 enhances Ad.7-induced GBM cell killing via
ER stress and autophagy and by decreasing expression of mitochondrial protective proteins“
Cancer Biol Ther, 9, 526-536
N. Baryawno N, B. Sveinbjörnsson, S. Eksborg, C.-S. Chen, P. Kogner, and J. I. Johnsen (2010)
“Small-Molecule Inhibitors of Phosphatidylinositol 3-Kinase/Akt Signaling Inhibit Wnt/β-Catenin
Pathway Cross-Talk and Suppress Medulloblastoma Growth”, Cancer Res, 70, 266-276
H. L. Chandler, T. R. Webb, C. A. Barden, M. Thangavelu, S. K. Kulp, C.-S. Chen, C. M. H.
Colitz (2010) “The effect of phosphorylated Akt inhibition on posterior capsule opacification in an
ex vivo canine model” Molecular vision, 16, 2202-2214
2009
82. P.-H. Huang, D. Wang. H.-C. Chuang, S. Wei, S. K. Kulp, and C.-S. Chen (2009) “-Tocopheryl
succinate and derivatives mediate the transcriptional repression of androgen receptor in prostate
cancer cells by targeting the PP2A-JNK-Sp1 signaling axis” Carcinogenesis 30, 1125-1131
(citations: 13)
83. S. Wei, H.-C. Chuang, W.-C. Tsai. H.-C. Yang. S.-R. Ho, A. J. Paterson, S. K. Kulp, and C.-S.
Chen (2009) “Thiazolidinediones mimic glucose starvation in facilitating Sp1 degradation through
the upregulation of -TrCP’ Mol. Pharmacol. 76, 47-57
84. Y.-T. Yang, C. Balch, S. K. Kulp, M. R. Mand, K. P. Nephew, and C.-S. Chen (2009) “A
rationally designed histone deacetylase inhibitor with distinct antitumor activity against ovarian
cancer” Neoplasia 11, 552-563 (citations: 33)
85. J.-R. Weng, C.-H. Tsai, H. Omar, A. M. Sargeant, D. Wang, S. K. Kulp, C. L. Shapiro, and C.-S.
Chen (2009) “OSU-A9, a Potent Indole-3-Carbinol Derivative, Suppresses Breast Tumor Growth
by Targeting the Akt-NF-kB Pathway and Stress Response Signaling” Carcinogenesis 30, 1702-
15
C.-S. Chen
86.
87.
88.
89.
90.
91.
92.
93.
94.
1709
D. Wang, H.-C. Chuang, S.-C. Weng, P.-H. Huang, H.-Y. Hsieh, S. K. Kulp, and C.-S. Chen
(2009) “-Tocopheryl Succinate as a Scaffold to Develop Potent Inhibitors of Breast Cancer Cell
Adhesion” J. Med. Chem. 52, 5642-5648
H. A. Omar, A. M. Sargeant, J.-R. Weng, D. Wang, S. K. Kulp, T. Patel, C.-S. Chen (2009)
“Targeting of the Akt-NF-kB Signaling Network by OSU-A9, a Novel Indole-3-Carbinol
Derivative, in a Mouse Model of Hepatocellular Carcinoma” Mol. Pharmacol. 76, 957-968
H.-C. Chiu, J. Yang, S. Soni, S. K. Kulp, J. S. Gunn, L. S. Schlesinger, C.-S. Chen (2009)
“Pharmacological Exploitation of an Off-Target Antibacterial Effect of the Cyclooxygenase-2
Inhibitor Celecoxib against Francisella tularensis” Antimicrob. Agents Chemother. 53, 2998-3002
H.-C. Chiu, S. K. Kulp, S. Soni, D. Wang, J. S. Gunn, L. S. Schlesinger, C.-S. Chen (2009)
“Eradication of Intracellular Salmonella enterica serovar Typhimurium with a Small-Molecule,
Host Cell-Directed Agent” Antimicrob. Agents Chemother. 53, 5236-5244
H.-C. Chiu, S. Soni, S. K. Kulp, H. Curry, D. Wang, J. S. Gunn, L. S. Schlesinger, and C.-S. Chen
(2009) “Eradication of intracellular Francisella tularensis in THP-1 human macrophages with a
novel autophagy inducing agent” J. Biomed. Sci. 16, 110-119
R. Lapalombella, A. Gowda, T. Joshi, N. Mehter, C. Cheney, A. Lehman, C.-S. Chen, A. J.
Johnson, M. A. Caligiuri, S. Tridandapani, N. Muthusamy, and J. C. Byrd (2009) “The humanized
CD40 antibody SGN-40 demonstrates pre-clinical activity that is enhanced by lenalidomide in
chronic lymphocytic leukaemia” Br. J. Haematol. 144, 848-855 (citations: 26)
T. X. Lee, M. D. Packer, J. Huang, E. M. Akhmametyeva, S. K. Kulp. C.-S. Chen, M. Giovannini,
A. Jacob, D. B. Welling, L. S. Chang (2009) “Growth inhibitory and anti-tumour activities of OSU03012, a novel PDK-1 inhibitor, on vestibular schwannoma and malignant schwannoma cells” Eur.
J. Cancer 45, 1709-1720 (citations: 25)
X. Contreras, M. Schweneker, C.-S. Chen, J. M. McCune, S. G. Deeks, J. Martin, and B. M.
Peterlin (2009) “Suberoylanilide hydroxamic acid reactivates HIV from latently infected cells” J.
Biol. Chem. 284, 6782-6789 (citations: 109)
S. Wei, J. Yang, S. –L. Lee, S. K. Kulp, and C.-S. Chen (2009) “PPAR-independent antitumor
effects of thiazolidinediones” Cancer Lett. 276, 119-124 (invited review) (citations: 45)
2008
95. Y.-C. Wang, S. K. Kulp, D. Wang, C.-C Yang, A. M. Sargeant, J.-H. Hung, Y. Kashida, M.
Yamaguchi, G.-D. Chang, and C.-S. Chen (2008) “Targeting Endoplasmic reticulum stress and Akt
with OSU-03012 and gefitinib or erlotinib to overcome resistance to epidermal growth factor
receptor inhibitors” Cancer Res. 68, 2820-2830 (citations: 27)
96. J.-H. Hung, Y.-S. Lu, Y.-C. Wang, Y.-H. Ma, D. Wang, S. K. Kulp, N. Muthusamy, J. C. Byrd, A.L. Cheng, and C.-S. Chen (2008) “FTY720 induces apoptosis in hepatocellular carcinoma cells
through activation of protein kinase C-delta signaling” Cancer Res. 68, 1204-1212 (citations: 58)
97. A.M. Sargeant, R. C. Rengel, S. K. Kulp, R. D. Klein, S. K. Clinton, Y.-C. Wang, and C.-S. Chen
(2008) “OSU-HDAC42, a histone deacetylase inhibitor, blocks prostate tumor progression in the
transgenic adenocarcinoma of the mouse prostate model” Cancer Res. 68, 3999-4009 (citations:
40)
98. S. Wei, H.-C. Yang, H.-C. Chuang, J. Yang, S. K. Kulp, P.-J. Lu. M.-D. Lai, and C.-S. Chen
(2008) “A novel mechanism by which thiazolidinediones facilitate the proteasomal degradation of
cyclin D1 in cancer cells” J. Biol. Chem. 283, 26759-26770 (citations: 35)
99. J. Yang, S. Wei, D. Wang, Y.-C. Wang, S. K. Kulp, and C.-S. Chen (2008) “Pharmacological
exploitation of the peroxisome proliferator-activated receptor  agonist ciglitazone to develop a
16
C.-S. Chen
100.
101.
102.
103.
104.
105.
106.
107.
108.
109.
110.
111.
novel class of androgen receptor-ablative agents” J. Med. Chem. 51, 2100-2107 (citations: 20)
S.-C. Weng, Y. Kashida, S. K. Kulp. D. Wang, R. W. Brueggemeier, C. L. Shapiro, and C.-S. Chen
(2008) “Sensitizing estrogen receptor-negative breast cancer cells to tamoxifen with OSU-03012, a
novel celecoxib-derived PDK-1/Akt signaling inhibitor” Mol. Cancer Ther. 7, 800-808 (citations:
30)
J.-R. Weng, C.-H. Tsai, S. K. Kulp, and C.-S. Chen (2008) “Indole-3-carbinol as a chemopreventive and anti-cancer agent” Cancer Lett. 262, 153-163 (Invited review) (citations: 109)
Q. Liu, X. Zhao, F. Frissora, Y. Ma, R. Santhanam, D. Jarjoura, A. Lehman, D. Perrotti, C.-S.
Chen, J. T. Dalton, N. Muthusamy, and J.C. Byrd (2008) “FTY720 demonstrates promising
preclinical activity for chronic lymphocytic leukemia and lymphoblastic leukemia/lymphoma”
Blood 111, 275-284 (citations: 77)
R. Lapalombella, B. Yu, G. Triantafillou, Q. Liu, J. P. Butchar, G. Lozanski, A. Ramanunni, L. L.
Smith, W. Blum, L. Andritsos, D. Wang, A. Lehman, C.-S. Chen, A. J. Johnson, G. Marcucci, R. J.
Lee, L. J. Lee, S. Tridandapani, N. Muthusamy, and J. C. Byrd (2008) “Lenalidomide downregulates the CD20 antigen and antagonizes direct and antibody-dependent cellular cytotoxicity of
rituximab on primary chronic lymphocytic leukemia cells” Blood 112, 5180-5189 (citations: 80)
M. A. Park, A. Yacoub, M. Rahmani, G. Zhang, L. Hart, M. P. Hagan, S. K. Calderwood, M. Y.
Sherman, C. Koumenis, S. Spiegel, C.-S. Chen, M. Graf, D. T. Curiel, P. B. Fisher, S. Grant and P.
Dent (2008) “OSU-03012 stimulates PKR-like endoplasmic reticulum-dependent increases in 70kDa heat shock protein expression, attenuating its lethal actions in transformed cells” Mol.
Pharmacol. 73, 1168-1184 (citations: 29)
H. Ding, C. Han, D. Guo, D. Wang, C.-S. Chen, and S. M. D’Ambrosio (2008) “OSU03012
activates Erk1/2 and Cdks leading to the accumulation of cells in the S-phase and apoptosis” Int J.
Cancer 123, 2923-2930 (citations: 7)
H. Ding, C. Han, D. Guo, D. Wang, W. Duan, C.-S. Chen, and S. M. D’Ambrosio (2008)
“Sensitivity to the non-COX inhibiting celecoxib derivative, OSU03012, is p21WAF1/CIP1
dependent” Int. J. Cancer 123, 2931-2938 (citation: 6)
M. A. Park, D. T. Curiel, C. Koumenis, M. Graf, C.-S. Chen, P. B. Fisher, S. Grant, P. Dent (2008)
“PERK-dependent regulation of Hsp70 expression and the regulation of autophagy” Autophagy 4,
364-367 (citations: 13)
L. A. Andritsos, A. J. Johnson, G. Lozanski, W. Blum, C. Kefauver, F. Awan, L. L. Smith, R.
Lapalombella, S. E. May, C. A. Raymond, D. Wang, R. D. Knight, A. S. Ruppert, A. Lehman, D.
Jarjoura, C.-S. Chen, J. C. Byrd (2008) “Higher doses of lenalidomide are associated with
unacceptable toxicity including life-threatening tumor flare in patients with chronic lymphocytic
leukemia” J. Clin. Oncol. 26, 2519-2525 (citations: 106)
M. Gao, P. Y. Yeh, Y.-S. Lu, C.-H. Hsu, K.-F. Chen, W.-C. Lee, W.-C. Feng, C.-S. Chen, M.-L.
Kuo, A.-L. Cheng (2008) “OSU-03012, a novel celecoxib derivative, induces reactive oxygen
species-related autophagy in hepatocellular carcinoma” Cancer Res. 68, 9348-9357 (citations: 57)
W. C. Kissebeth, S. Murahari, C.A. London, S. K. Kulp, C.-S. Chen (2008) “Evaluation of the
effects of histone deacetylase inhibitors on cells from canine cancer cell lines” American Journal of
Veterinary Research 69, 938-945 (citations: 8)
P. Neviani, R. Santhanam, Y. Ma, G. Marcucci, J. C. Byrd, C.-S. Chen, J. Cortes, M. A. Caligiuri,
C. Huettner, R. Bhatia, D.-C. Roy, D. Perrotti (2008) “Activation of PP2A by FTY720 Inhibits
Survival and Self-Renewal of the Ph(+) Chronic Myelogenous Leukemia (CML) CD34(+)/CD38(-)
Stem Cell through the Simultaneous Suppression of BCR/ABL and BCR/ABL-independent
Signals” Blood 112, 77-77 (citations: 8)
2007
17
C.-S. Chen
112. Y.-S. Lu, Y. Kashida, S. K. Kulp, Y.-C. Wang, D. Wang, J.-H. Hung, M. Tang, Z.-Z. Lin, T.-J.
Chen, A.-L. Cheng, and C.-S. Chen (2007) “Efficacy of a novel histone deacetylase inhibitor in
murine models of hepatocellular carcinoma” Hepatology 46, 1119-1130 (citations: 50)
113. C.-C. Yang, Y.-C. Wang, S. Wei, C.-S. Chen, C.-C. Lee, C.-C. Lin, and C.-S. Chen (2007)
“Peroxisome proliferator-activated receptor gamma-independent suppression of androgen receptor
expression by troglitazone mechanism and pharmacologic exploitation” Cancer Res., 67, 32293238 (citations: 31)
114. C.-S. Chen, Y.-C. Wang, H.-C. Yang, P.-H. Huang, S. K. Kulp, C-C. Yang, Y.-S. Lu, S.
Matsuyama, C.-Y. Chen, and C.-S. Chen (2007) “Histone Deacetylase Inhibitors Sensitize Prostate
Cancer Cells to Agents That Produce DNA Double-Strand Breaks by Targeting Ku70 Acetylation”
Cancer Res., 67, 5318-5327 (citations: 106)
115. J.-R. Weng, C.-H. Tsai, S. K. Kulp. D. Wang, C.-H. Lin, H.-C. Yang, Y. Ma, A. Sargeant, C.-F.
Chiu, M.-H. Tsai, and C.-S. Chen (2007) “A potent indole-3-carbinol-derived antitumor agent with
pleotropic effects on multiple signaling pathways in prostate cancer cells” Cancer Res. 67, 78157824 (citations: 38)
116. A. M. Sargeant, R. D. Klein, R. C. Rengel, S. K. Clinton, S. K. Kulp, Y. Kashida, M. Yamaguchi,
and C.-S. Chen (2007) “Chemopreventive and bioenergetic signaling effects of PDK1/Akt pathway
inhibition in a transgenic mouse model of prostate cancer” Toxicol. Pathol. 35, 549-561 (citations:
24)
117. K. To, Y. Zhao, H. Jiang, K. Hu, M. Wang, J. Wu, C. Lee, D. W. Yokom, A. L. Stratford, U.
Klinge, P. R. Mertens, C.-S. Chen, M., Bally, D. Yapp, S. E Dunn (2007) “The phosphoinositidedependent kinase-1 inhibitor, OSU-03012, prevents Y-box binding protein-1 (YB-1) from inducing
epidermal growth factor receptor (EGFR)” Mol. Pharmacol., 72, 641-652 (citations: 26)
118. S. Wei, L.-F. Lin, C.-C. Yang, Y.-C. Wang, G.-D. Chang, H. Chen, and C.-S. Chen (2007)
“Thiazolidineiones modulate the expression of -catenin and other cell-cycle regulatory proteins by
targeting the F-box proteins of Skp1-Cul1-F-box protein E3 ubiquitin ligase independently of
PPAR” Mol. Pharmacol. 72, 725-733 (citations: 33)
119. L. M. Porchia, M. Guerra, Y. C. Wang, Y. Zhang, A. V. Espinosa, M. Shinohara, S. K. Kulp, L. S.
Kirschner, M. Saji, C.-S. Chen, and M. D. Ringel (2007) “2-amino-N-{4-[5-(2-phenanthrenyl)-3(trifluoromethyl)-1H-pyrazol-1-yl]-phenyl}acetamide (OSU-03012), a celecoxib derivative,
directly targets p21-activated kinase” Mol. Pharmacol. 72(5):1124-1131 (citations: 41)
120. B. J. Dewar, O. S. Gardner, C.-S. Chen, H. S. Earp, J. M. Samet, and L. M. Graves (2007)
“Capacitative calcium entry contributes to the differential transactivation of the epidermal growth
factor receptor in response to thiazolidinediones” Mol. Pharmacol. 72:1146-1156 (citations: 17)
121. L. Cen, F.-C. Hsieh, H.-J. Lin, C.-S. Chen, S. J. Qualman, and J. Lin (2007) “PDK-1/Akt pathway
as a novel therapeutic target in rhabdomyosarcoma cells using OSU-03012 compound” Br. J.
Cancer, 97, 785-791 (citations: 37)
122. P. Neviani, R. Santhanam, J. J. Oaks, A. M. Eiring, M. Notari, B. W. Blaser, S. Liu, R. Trotta, N.
Muthusamy, C. Gambacorti-Passerini, B. J. Druker , J. Cortes, G. Marcucci, C.-S. Chen, N. M.
Verrills , D. C. Roy, M. A. Caligiuri, C. D. Bloomfield, J. C. Byrd, and D. Perrotti (2007)
“FTY720, a new alternative for treating blast crisis chronic myelogenous leukemia and Philadelphia
chromosome-positive acute lymphocytic leukemia” J. Clin. Invest. 117(9):2408-2421 (citations:
185)
123. J. B. Garrison, Y.-J. Shaw, C.-S. Chen, and N. Kyrianou (2007) “ Novel quinazoline-based
compounds impair prostate tumorigenesis by targeting tumor vascularity” Cancer Res. 67, 1134411352 (citations: 30)
124. S. Zhang, A. Suvannasankha, C.D. Crean, V.L. White, A. Johnson, C.S. Chen, S.S. Farag “OSU-
18
C.-S. Chen
03012, a novel celecoxib derivative, is cytotoxic to myeloma cells and acts through multiple
mechanisms” Clin Cancer Res 13 (2007) 4750-4758 (citations: 37)
125. F. J. Alvarez, S. Murahari, C. G. Couto, T. J. Rosol, S. K. Kulp, C.-S. Chen, W. C. Kisseberth
(2007) “3-Phosphoinositide-dependent protein kinase-1/Akt signalling and inhibition in a canine
prostate carcinoma cell line”, Veterinary and Comparative Oncology, 5 , 47-58 (ciations: 1)
2006
126. C.-W. Shiau, J.-W. Huang, D.-S. Wang, J.-R. Weng, C.-C. Yang, C.-H, Lin, C. Li, and C.-S. Chen
(2006) “-Tocopheryl Succinate Induces Apoptosis in Prostate Cancer Cells in part through
Inhibition of Bcl-xL/Bcl-2 Function” J. Biol. Chem., 281, 11819-11825 (citations: 87)
127. C.-C. Yang, C.-Y. Ku, S. Wei, C.-W. Shiau, C.-S. Chen, J. J. Pinzone, M. D. Ringel, and C.-S.
Chen (2006) “Peroxisome Proliferator-Activated Receptor -Independent Repression of ProstateSpecific Antigen Expression by Thiazolidinediones in Prostate Cancer Cells” Mol Pharmacol, 69,
1564-1570 (citations: 33)
128. P.-H. Tseng, Y.-C. Wang, S.-C. Weng, J.-R. Weng, C.-S. Chen, R. W. Brueggemeier, C. L.
Shapiro, C.-Y. Chen, S. E. Dunn, M. Pollak, and C.-S. Chen (2006) “Overcoming trastuzumab
resistance in HER2-overexpressing breast cancer cells by using a novel celecoxib-derived
phosphoinositide-dependent kinase-1 inhibitor” Mol. Pharmacol., 70, 1534-1541 (citations: 41)
129. H.-Y. Lin, C.-S. Chen, S.-P. Lin, J.-R. Weng, and C.-S. Chen (2006) Targeting Histone
Deacetylase in Cancer Therapy Med. Res. Rev., 26, 397-413 (citations: 171)
130. J.-R. Weng, C.-Y. Chen, J. J. Pinzone, M.D. Ringel, and C.-S. Chen (2006) Beyond PPAR-
Signaling. The Multi-Facets of the Antitumor Effect of Thiazolidinediones Endocrine-Related
Cancer, 13, 401-413 (citations: 116)
131. J. W. Huang, C.-W. Shiau, J. Yang, D.-S. Wang, H.-C. Chiu, C.-Y. Chen, and C.-S. Chen (2006)
“Development of Small-Molecule Cyclin D1-Ablative Agents” J. Med. Chem., 49, 4684-4689
(citations: 44)
132. S. K. Kulp, C.-S. Chen, D. Wang, C.-Y. Chen, and C.-S. Chen (2006) “Antitumor effects of a
novel phenyl-butyrate-based histone deacetylase inhibitor, (S)-HDAC-42, in prostate cancer” Clin.
Cancer Res., 12, 5199-5206 (citations: 63)
133. A. Yacoub, M. A. Park, D. Hanna, Y. Hong, C. Mitchell, A. P. Pandya, H. Harada, G. Powis, C.-S.
Chen, C. Koumenis, S. Grant, and P. Dent (2006) “OSU-03012 promotes caspase-independent but
PERK-, cathepsin B-, BID-, and AIF-dependent killing of transformed cells” Mol. Pharmacol. 70,
589-603 (citations: 57)
134. Z. Tong, X. Wu, C.-S. Chen, and J. P. Kehrer (2006) “Cytotoxicity of a non-cyclooxygenase-2
inhibitor derivative of celecoxib in non-small-cell lung cancer A549 cells” Lung Cancer 52, 117124 (citations: 19)
135. P. Pyrko, N. Soriano, A. Kardosh, Y.-T. Liu, J. Uddin, N. A. Petasis, F. M. Hofman, C.-S. Chen, T.
C Chen, and A. H. Schönthal (2006) “Downregulation of survivin expression and concomitant
induction of apoptosis by celecoxib and its non-cyclooxygenase-2-inhibitory analog, dimethylcelecoxib (DMC), in tumor cells in vitro and in vivo” Mol. Cancer 5:19 (citations: 82)
136. R. E. Teresi, C.-W. Shaiu, C.-S. Chen, V. K. Chatterjee, K. A. Waite, and C. Eng (2006)
“Increased PTEN expression due to transcriptional activation of PPAR by Lovastatin and
Rosiglitazone” Int. J. Cancer, 118, 2390-2398 (citations: 83)
137. J. Li, J. Zhu, W. S. Melvin, T. S., Bekaii-Saab, C.-S. Chen, P. Muscarella (2006) “A structurally
optimized celecoxib derivative inhibits human pancreatic cancer cell growth” J. Gastrointest. Surg.
10, 207-214 (citations: 22)
138. K. K. Chan, P. Chen, Z. Xie, S. K. Kulp, C.-S. Chen, J. M. Covey (2006) “Pharmacokinetics of
19
C.-S. Chen
Akt inhibitor NSC 728209 in the rat by LC/MS/MS method”, EJC Supplements, 4, 182-182
(citation: 1)
2005
139. C.-W. Shiau, C.-C. Yang, S. K. Kulp, K.-F. Chen, J.-W. Huang, and C.-S. Chen (2005)
“Thiazolidenediones mediates apoptosis in prostate cancer cells, in part, via the inhibition of BclxL/Bcl-2 functions independently of PPAR” Cancer Res., 65, 1561-1569 (citations: 181)
140. P.-H. Tseng, H.-P. Lin, J. Zhu, K.-F. Chen, E. M. Hade, D. C. Yang, J.C. Byrd, M. Grever, K.
Johnson, B. J. Druker, and C.-S. Chen (2005) “synergistic interactions between imatinib mesylate
and the novel phosphoinositide-dependent kinase-1 inhibitor OSU-03012 in overcoming imatinib
mesylate resistance” Blood, 105, 4021-4027 (citations: 77)
141. J.-W. Huang, C.-W. Shiau, Y.-T. Yang, S. K. Kulp, K.-F. Chen, R. W. Brueggemeier, C. L.
Shapiro, and C.-S. Chen (2005) “Peroxisome Proliferator-Activated Receptor -Independent
Ablation of Cyclin D1 by Thiazolidinediones and Their Derivatives in Breast Cancer Cells” Mol
Pharmacol, 67, 1342-1348 (citations: 108)
142. C.-S, Chen, S.-C. Weng, P.-H. Tseng, H.-P. Lin, and C.-S. Chen (2005) “Histone acetylationindependent effect of histone deacetylase inhibitors on Akt through the reshuffling of protein
phosphatase 1 complexes” J. Biol. Chem., 280, 38879-38887 (citations: 158)
143. Q. Lu, D.-S. Wang, C.-S. Chen, Y.D. Hu, and C.-S. Chen (2005) “Structure-based optimization of
phenylbutyrate-derived histone deacetylase inhibitors” J. Med. Chem. 48, 5530-5535 (citations: 53)
144. S. K. Kulp, K.-F. Chen, and C.-S. Chen (2005) “Chemotherapy for prostate cancer” in Prostate
Cancer. Basic mechanisms and Therapeutic Approaches (Ed., C. Chang) World Scientific, New
Jersey, pp. 365-382
145. A. J. Johnson, L. L. Smith, J. Zhu, N. A. Heerema, S. Jefferson, A. Mone, M. Grever, C.-S. Chen,
J. C. Byrd (2005) “A novel celecoxib derivative, OSU03012, induces cytotoxicity in primary CLL
cells and transformed B-cell lymphoma cell line via a caspase- and Bcl-2-independent mechanism”
Blood, 105, 2504-2509 (citations: 57)
146. H. Ding, C. Han, J. Zhu, C.-S. Chen, and S. M. D’Ambrosio (2005) “Celecoxib derivatives induce
apoptosis via the disruption of mitochondrial membrane potential and activation of caspase 9” Int.
J. Cancer, 113, 803-810 (citations: 125)
147. O.S. Gardner, C.-W. Shiau, C.-S. Chen, and L.M. Graves (2005) “PPAR-independent activation
of p38 MAPK by thiazolidinediones involves calcium/calmodulin-dependent protein kinase II and
protein kinase R: correlation with endoplasmic reticulum stress” J. Biol. Chem., 280, 10109-10118
(citations: 71)
148. J.E. Kucab, C. Lee, C.-S. Chen, J. Zhu, C. B. Gilks, M. Cheang, D. Huntsman, E. Yorida, J.
Emerman, M. Pollak, S. E. Dunn (2005) “Celecoxib analogues disrupt Akt signaling, which is
commonly activated in primary breast tumours” Breast Cancer Res. 2005, 7:R796-R807 (citations:
82)
149. Z. Tong, X. Wu, D. Ovcharenko, J. Zhu, C.-S. Chen, J. P. Kehrer (2005) “Neutrophil gelatinase
associated lipocalin as a survival factor” Biochem. J. 391, 441-448 (citations: 141)
2004
150. S. K. Kulp, Y.-T. Yang, C.-C. Hung, K.-F. Chen, J.-P. Lai, P.-H. Tseng, J. W. Fowble, P. J. Ward,
and C.-S. Chen (2004) “3-phosphoinositide-dependent protein kinase-1/Akt signaling represents a
major cyclooxygenase-2-independent target for celecoxib in prostate cancer cells” Cancer Res., 64,
1444-1451 (citations: 210)
151. Q. Lu, Y.-T. Yang, C.-S. Chen, M. Davis, J. C. Byrd, M. R. Etherton, A. Umar, and C.-S. Chen
(2004) “Zn2+-Chelating Motif-Tethered Short-Chain Fatty Acids as a Novel Class of Histone
20
C.-S. Chen
152.
153.
154.
155.
156.
Deacetylase Inhibitors” J. Med. Chem., 47, 467-474 (citations: 82)
J. Zhu, J.-W. Huang, P.-H. Tseng, Y.-T. Yang, J. Fowble, C.-W. Shiau, Y-J. Shaw, S. K. Kulp, and
C.-S. Chen (2004) “From the cyclooxygenase-2 inhibitor celecoxib to a novel class of 3phosphoinositide-dependent protein kinase-1 inhibitors” Cancer Res. 64, 4309-4318 (citations:
215)
P.-H. Tseng, H.-P. Lin, H. Hu, C. Wang, M. X. Zhu, and C.-S. Chen (2004) “The canonical
transient receptor potential 6 channel as a putative phosphatidylinositol 3,4,5-trisphosphatesensitive calcium entry system” Biochemistry, 43, 11701-11708 (citations: 67)
Y.-J. Shaw, Y.-T. Yang, J. B. Garrison, N. Kyprianou, and C.-S. Chen (2004) “Pharmacological
exploitation of the 1-adrenoreceptor antagonist doxazosin to develop a novel class of antitumor
agents that block intracellular Akt activation” J. Med. Chem., 47, 4453-4462 (citations: 36)
H.-P. Lin, S. K. Kulp, P.-H. Tseng, Y.-T. Yang, C.-S. Chen, and C.-S. Chen (2004) “Growthinhibitory effects of celecoxib in human umbilical vein endothelial cells are mediated through G1
arrest via multiple signaling mechanisms” Mol. Cancer Ther., 3, 1671-1680 (citations: 59)
R. Roychowdhury, R. A. Baiocchi, S. Vourganti, D. Bhatt, B.W. Blaser, A. G. Freud, J. Chou, C.-S.
Chen, J. J. Xiao, M. Parthun, K. K. Chan, C.F. Eisenbeis, A. K. Ferketich, M. R. Grever, C.-S.
Chen, M.A. Caligiuri (2004) “Selective efficacy of depsipeptide in a xenograft model of EpsteinBarr virus-positive lymphoproliferative disorder” J. Natl. Cancer Inst. 96, 1447-1457 (citations:
24)
2003
157. C.-C. Yang, H.-P. Lin, C.-S. Chen, Y.-T. Yang, P.-H. Tseng, V. M. Rangnekar, and C.-S. Chen
(2003) “Bcl-xL Mediates a Survival Mechanism Independent of the Phosphoinositide 3-Kinase/Akt
Pathway in Prostate Cancer Cells” J. Biol. Chem., 278, 25872-25878 (citations: 82)
158. S. K. Kulp, X. Song, H.-P. Lin, A. Johnson, and C.-S. Chen (2003) “COX-2 in Cancer, a Role yet
to be Defined” Proceedings of the 5th International Congress on Essential Fatty Acids and
Ecosanoids”, AOAC Press, Champaign, IL, p155-168
2002
159. X. Song, H.-P. Lin, A. J. Johnson, P.-H. Tseng, Y.-T. Yang, S. K. Kulp, and C.-S. Chen (2002)
“Cyclooxygenase-2, player or spectator in cyclooxygenase-2 inhibitors-induced apoptosis in
prostate cancer cells” J. Natl. Cancer Inst., 94, 585-591 (citations: 259)
160. J. Zhu, X. Song, H.-P. Lin, S. Yan, V. E. Marquez, and C.-S. Chen (2002) “Using cycoloxygenase2 inhibitors as molecular platforms to develop a new class of apoptosis-inducing agents” J. Natl.
Cancer Inst., 94, 1745-1757 (citations: 154)
161. A. J. Johnson, A.-L. Hsu, H.-P. Lin, X. Song, and C.-S. Chen (2002) “The Cyclooxygenase-2
Inhibitor Celecoxib Perturbs Intracellular Calcium by Inhibiting Endoplasmic Reticulum Ca2+ATPases. A Plausible Link with Its Antitumor Effect and Cardiovascular Risks” Biochem. J., 366,
831-837 (citations: 127)
2001
162. T.-T. Ching, A.-L. Hsu, A. J. Johnson, and C.-S. Chen (2001) “Phosphoinositide 3-kinase
facilitates antigen-stimulated Ca(2+) influx in RBL-2H3 mast cells via a phosphatidylinositol 3,4,5trisphosphate-sensitive Ca(2+) entry mechanism” J. Biol. Chem., 276, 14814-14820 (citations: 76)
163. T.-T. Ching, H.-P. Lin, C.-C. Yang, M. Oliveira, P.-J. Lu, and C.-S. Chen (2001) “Specific binding
of the C-terminal Src homology 2 domain of the p85 subunit of phosphoinositide 3-kinase to
phosphatidylinositol 3,4,5-trisphosphate. Localization and engineering of the phosphoinositidebinding motif” J. Biol. Chem., 276, 43932-43938 (citations: 21)
21
C.-S. Chen
164. A. J. Johnson, X. Song, A.-L. Hsu, and C.-S. Chen (2001) “Apoptosis signaling pathways mediated
by cyclooxygenase-2 inhibitors in prostate cancer cells” Adv. Enzyme Regul., 41, 221-235
(citations: 76)
165. A. Gagnon, P. Dods, N. Roustan-Delatour, C.-S. Chen, and A. Sorisky (2001)
“Phosphatidylinositol 3,4,5-trisphosphate is required for IGF-1-mediated survival of 3T3-L1
preadipocytes” Endocrinology, 142, 205-212 (citations: 54)
166. D.-S. Wang, A. L. Hsu, and C.-S. Chen (2001) “A phosphatidylinositol 3,4,5-trisphosphate
analogue with low serum protein-binding affinity” Bioorg. Med. Chem., 9, 133-139 (citations: 7)
167. D.-S. Wang, and C.-S. Chen (2001) “Synthesis and biological evaluations of L-a-phosphatidyl-D3-deoxy-3-heteromethyl-myo-inositol as PI 3-kinase inhibitors” Bioorg. Med. Chem., 9, 3165-3172
(citations: 7)
168. J. R. Halstead, M. Roefs, C. D. Ellson, S. D'Andrea, C.-S. Chen, C. S. D'Santos, N. Divecha (2001)
“A novel pathway of cellular phosphatidylinositol(3,4,5)-trisphosphate synthesis is regulated by
oxidative stress” Curr. Biol., 11, 386-395 (citations: 38)
169. H. Mansour, D.-S. Wang, C.-S. Chen, and G. Zografi (2001) “Comparison of bilayer and
monolayer properties of phospholipid systems containing dipalmitoylphosphatidylglycerol and
dipalmitoylphos-phatidylinositol” Langmuir, 17, 6622-6632 (citations: 27)
2000
170. A.-L. Hsu, T.-T. Ching, D.-S. Wang, X. Song, V. M. Rangnekar, and C.-S. Chen (2000) “The
Cyclooxygenase-2 inhibitor celecoxib induces apoptosis by blocking Akt activation in human
prostate cancer cells independently of Bcl-2” J. Biol. Chem., 275, 11397-11403 (citations: 668)
171. A.-L. Hsu, T.-T. Ching, G. Sen, D.-S. Wang, S. Bondada, K. S. Authi, and C.-S. Chen (2000)
“Novel function of phosphoinositide 3-kinase in T-cell Ca2+ signaling. A phosphatidylinositol
3,4,5-trisphosphate-mediated Ca2+ entry mechanism” J. Biol. Chem, 275, 16242-16250 (citations:
51)
172. D.-S. Wang, T.-T. Ching, J. St. Pyrek, and C.-S. Chen (2000) “Biotinylated phosphatidylinositol
3,4,5-trisphosphate as affinity ligand” Anal. Biochem., 280, 301-307 (citations: 15)
1999
173. P.-J. Lu, D. Wang, K.-M. Lin, H. L. Yin, and C.-S. Chen (1999) "Differential recognition of
phosphoinositides by actin regulating proteins and its physiological implications" in
Phosphoinositides. Chemistry, Biochemistry, and Biomedical Applications (Bruzik, K. S., ed.)
ACS Symposium Series 718, American Chemical Society, Washington, D.C., pp38 – 54
174. T.-T, Ching, D. Wang, A.-L. Hsu, P.-J. Lu, and C.-S. Chen (1999) “Identification of multiple
phosphoinositide-specific phospholipases D as new regulatory enzymes for phosphatidyl-inositol
3,4,5-trisphosphate” J. Biol. Chem., 274, 8611-8617 (citations: 22)
175. A. Gagnon, C.-S. Chen, and A. Sorisky (1999) “Activation of protein kinase B and induction of
adipogenesis by insulin in 3T3-L1 preadipocytes. Contribution of phosphoinositide-3,4,5trisphosphate versus phosphoinositide-3,4-bisphosphate” Diabetes, 48, 691-698 (citations: 54)
176. M. Sarkari, B. L. Knutson, and C.-S. Chen (1999) "Enzymatic catalysis in cosolvent modified
pressurized organic solvents" Biotechnol. Bioeng. 65, 258-264 (citations: 10)
1998
177. P.-J. Lu, A.-L. Hsu, D. Wang, H. Y. Yan, H. L. Yin, and C.-S. Chen (1998) “Phosphoinositide 3kinase in rat liver nuclei” Biochemistry, 37, 5738-5745 (citations: 79)
178. P.-J. Lu, A.-L. Hsu, D. Wang, and C.-S. Chen (1998) “Phosphatidylinositol 3,4,5-trisphosphate
triggers platelet aggregation by activating Ca2+ influx” Biochemistry, 37, 9776-9783 (citations: 30)
179. A.-L. Hsu, P.-J. Lu, and C.-S. Chen (1998) “Regulation of nuclear calcium uptake by inositol
22
C.-S. Chen
180.
181.
182.
183.
184.
phosphates and external calcium” Biochem. Biophys. Res. Commun. 243, 653-656 (citations: 16)
D. Wang, A.-L. Hsu, X. Song, C.-M. Chiou, and C.-S. Chen (1998) “Molecular recognition at the
PtdIns(3,4,5)P3-binding site.
Studies with the permuted isomers of phosphatidylinositol
trisphosphate” J. Org. Chem, 63,5430-5437 (citations: 15)
Y. S. Bae, L. G. Cantley, C.-S. Chen, S.-R. Kim, K.-S. Kwon, and S. G. Rhee (1998) “Activation
of phospholipase C- by phosphatidylinositol 3,4,5-trisphosphate” J. Biol. Chem., 273, 4465-4469
(citations: 310)
M. Chou, W. Hou, J. Johnson, L. K. Graham, M. H. Lee, C.-S. Chen, A. C. Newton, B. S.
Schaffausen, A. Toker (1998) “Regulation of protein kinase C zeta by PI 3-kinase and PDK-1”
Curr. Biol., 8, 1069-1077 (citations: 596)
H. Banfic, X. Tang, I. H. Batty, C.P. Downes, C.-S. Chen, and S. E. Rittenhouse (1998) “A novel
integrin-activated pathway forms PKB/Akt-stimulatory PtdIns(3,4)P2 via PtdIns3P in platelets” J.
Biol. Chem., 273:13-16 (citations: 126)
Venkataraman, P.-J. Lu, C.-S. Chen, J. C. Cambier, and S. Bondada (1998) “CD72 mediated B cell
activation involves recruitment of CD19 and activation of phosphatidylinositol 3-kinase” Eur. J.
Immunol., 28, 3003-3016 (citations: 49)
1997
185. P.-J. Lu, and C.-S. Chen (1997) “Selective recognition of phosphatidylinositol 3,4,5-trisphosphate
by a synthetic peptide” J. Biol. Chem., 272, 466-472 (citations: 39)
186. M. P. Derman, A. Toker, J. H. Hartwig, K. Spokes, J. R. Falck, C.-S. Chen, L. C. Cantley, and L.
G. Cantley (1997) “ The lipid products of phosphoinositide 3-kinase increase cell motility through
protein kinase C” J. Biol. Chem., 272, 6465-6470 (citations: 137)
187. K.-M. Lin, E. Weneigeme, P.J. Lu, C.-S. Chen, and H. L. Yin (1997) “Gelsolin binding to
phosphatidylinositol 4,5-bisphosphate is modulated by calcium and pH” J. Biol. Chem., 272,
20443-20450 (citations: 72)
188. L.E. Rameh, A. K. Arvidsson, K. L. Carraway III, A. D. Couvillon, G. Rathbun, A. Crampton, B.
VanReterghem, M. P. Czech, K. S. Ravichandran, S. J. Burakoff, D.-S. Wang, C.-S. Chen, and L.
C. Cantley (1997) “A comparative analysis of the phosphoinositide binding specificity of pleckstrin
homology domains” J. Biol. Chem., 272, 22059-22066 (citations: 447)
1996
189. C.-Y. Chen, V.F. Pang, and C.-S. Chen (1996) “Pathologicla nd biochemical modifications of renal
functions in ibuprofen-induced interstitial nephritis” Renal Failure, 18, 31-40 (citations: 9)
190. C.-N. Chen, P.C. Wang, H.-F. Song, Y.C. Liu, and C.-S. Chen (1996) “Non-invasive detection of
ibuprofen in vivo 13C-NMR signals in rats” Chem. Pharm. Bull. 44, 204-207 (citations: 6)
191. P.-J. Lu, W.-R. Shieh, and C.-S. Chen (1996) "Antagonistic effect of inositol pentakisphosphate on
inositol trisphosphate receptor" Biochem. Biophys Res. Comm., 220, 637-642 (citations: 2)
192. C. J. Sih, G. Girdaukas, C.-S. Chen, and J.C. Sih (1996) “Enzymatic resolutions of alcohols, esters,
and nitrogen-containing compounds” in Enzymatic Reactions in Organic Media (A.M.P. Koskinen
and A.M. Klibanov, eds.) pp94-139, Blackie Academic & Professional (An Import of Chapman &
Hall), London
193. C. Q. Vu, P.-J. Lu, C.-S. Chen, and M. K. Jacobson (1996) "2'-Phospho-cyclic ADP-ribose, a
calcium mobilizing agent derived from NADP" J. Biol. Chem., 271, 4747-4754 (citations: 56)
194. D.-S. Wang, and C.-S. Chen (1996) “Synthesis of the D-3 series of phosphatidylinositol
polyphosphates” J. Org. Chem., 61, 5905-5910 (citations: 56)
195. P.-J. Lu, W.-R. Shieh, S. G. Rhee, H. L. Yin, and C.-S. Chen (1996) “Lipid products of
23
C.-S. Chen
phosphoinositide 3-kinase bind human profilin with high affinity” Biochemistry, 35, 14027-14034
(citations: 119)
196. W. S. Sossin, C.-S. Chen, A. Toker (1996) “Stimulation of an insulin receptor activates and downregulates the Ca2+-independent protein kinase C, Apl II, through a wortmannin-sensitive signaling
pathway in Aplysia” J. Neurochem., 67, 220-228 (citations: 26)
197. P.-J. Lu and C.-S. Chen (1996) “Modulation of the inositol 1,4,5-trisphosphate receptor by inositol
phosphates” Phosphorus, Sulfur, and Silicon Vol. 109-110, pp.325-328 (invited)
1995
198. C.-Y. Chen, and C.-S. Chen (1995) “Stereoselective disposition of ibuprofen in patients with
compromised renal hemodynamics” Br. J. Clin. Pharmacol., 40, 67-72 (citations: 16)
199. W.-R. Shieh, and C.-S. Chen (1995) “Preparation and characterization of a D-myo-inositol 1,4,5
trisphosphate-specific antibody” Biochem. J., 311, 1009-1014 (citations: 2)
200. L. E. Rameh, C.-S. Chen, and L. C. Cantley (1995) “Phosphatidylinositol (3,4,5)P3 interacts with
SH2 domains and modulates PI 3-kinase association with tyrosine-phosphorylated proteins” Cell,
83, 821-830 (citations: 289)
201. A. Toker, C. Bachelot, C.-S. Chen, J.R. Falck, J.H. Hartwig, L.C. Cantley, and T.J. Kovacsovics
(1995) “Phosphorylation of the platelet p47 phosphoprotein is mediated by the lipid products of
phosphoinositide 3-kinase” J. Biol. Chem., 270, 29525-29531 (citations: 80)
1994
202. C.-Y. Chen, and C.-S. Chen (1994) “Stereoselective disposition of ibuprofen in patients with renal
dysfunction” J. Pharmacol. Expt. Ther., 268, 590-594 (citations: 16)
203. D.-M. Gou, W.-R. Shieh, P.-J. Lu, and C.-S. Chen (1994) “D-myo-inositol 1,4,5-trisphosphate
analogues as useful tools in biochemical studies of intracellular calcium mobilization” Bioorg.
Med. Chem., 2, 7-13 (citations: 6)
204. C.-Y. Chen, V. F. Pang, and C.-S. Chen “Assessment of ibuprofen-associated nephrotoxicity in
renal insufficiency” J. Pharmacol. Expt. Ther., 270, 1307-1312 (citations: 7)
205. P.-J. Lu, D.-M. Gou, W.-R, Shieh, and C.-S. Chen (1994) “Molecular interactions of endogenous
D-myo-inositol phosphates with the intracellular Ins(1,4,5)P3 recognition site” Biochemistry, 33,
11586-11597 (citations: 45)
206. D.-M. Gou, and C.-S. Chen (1994) “Synthesis of L-a-phosphatidyl-D-myo-inositol 3,4,5trisphosphate, an important intracellular signaling molecule” J. Chem. Soc. Chem. Comm., 21252126 (citations: 16)
207. M. Liscovitch, V. Chalifa, P. Pertiles, C.-S. Chen, and L. C. Cantley (1994) “Novel function of
phosphatidylinositol 4,5-bisphosphate as a cofactor for brain membrane phospholipase D” J. Biol.
Chem., 269:21403-21406 (citations: 292)
208. D.-M. Gou, Y.-C. Liu, and C.-S. Chen (1994) “Mucor meihei lipase enantioselective
transformation of methyl trans-b-phenyl glycidate with isobutyl alcohol” in Preparative
Biotransformation (S.M. Roberts, ed) 5:1.2-5:1.8, John Wiley & Sons Ltd, New York
209. Ditullio, D., Anderson, D., C.-S. Chen, and C.J. Sih (1994) “L-Carnitine via enzyme-catalyzed
oxidative kinetic resolution” Bioorg. Med. Chem., 2, 415-420 (citations: 10)
1993
210. C.-S. Chen, D.-M. Gou, W.-R. Shieh, and Y.-C. Liu (1993) “Biocatalytic resolution of DLpropranolol. A successful example of Computer-Aided substrate design” Tetrahedron, 49, 32813290 (citations: 7)
211. W.-R. Shieh, and C.-S. Chen (1993) “Purification and characterization of novel “2-aryl-propionyl-
24
C.-S. Chen
CoA epimerase" from rat liver cytosol and mitochondria” J. Biol. Chem., 268, 3487-3493
(citations: 76)
13
212. W.-R. Shieh, Da-Ming Gou, Y.-C. Liu, C.-S. Chen, and C.-Y. Chen (1993) “ C NMR study on
ibuprofen metabolism in isolated rat liver mitochondria” Anal. Biochem., 212, 143-149 (citations:
6)
213. D.-M. Gou, Y.-C. Liu, and C.-S. Chen (1993) "A practical chemoenzymatic synthesis of the taxol
C-13 side chain N-benzoyl-(2R,3S)-3-phenylisoserine” J. Org. Chem., 58, 1287-1289 (citations:
144)
1992
214. D.-M. Gou, and C.-S. Chen (1992) "An efficient route to D-myo-inositol 1,3,4-triphosphate and Dmyo-inositol 1,3,4,5-tetrakisphosphate" Tetrahedron Lett., 33, 721-724 (citations: 25)
215. D.-M. Gou, Y.-C. Liu, and C.-S. Chen (1992) "An efficient chemoenzymatic access to optically
active myo-inositol polyphosphates" Carbohydr. Res., 234, 51-64 (citations: 35)
216. C.-S. Chen, and Y.-C. Liu (1992) "Stereochemical recognition in lipase catalysis" J. Jpn. Oil
Chem. Soc., 41, 724-733 (invited) (citations: 7)
217. C.-Y. Chen, W.-R. Shieh, and C.-S. Chen (1992) “Clinical implication of using racemic drugs”,
Clin. Res. and Regul. Affairs, 9, 247-259 (I can’t find it) (citations: 2)
1991
218. C.-S. Chen, and Y.-C. Liu (1991) "Amplification of enantioselectivity in biocatalyzed kinetic
resolution of racemic alcohols" J. Org. Chem., 56, 1966-1968 (citations: 30)
219. C.-Y. Chen, P.-H. Lu, W.-R. Shieh, S. Harriman, and C.-S. Chen (1991) "Metabolic stereoisomeric
inversion of ibuprofen in mammals" Biochim. Biophys. Acta, 1078, 411-417 (citations: 75)
220. C.-Y. Chen, P.-H. Lu, and C.-S. Chen (1991) "Metabolic inversion of stereoisomeric ibuprofen in
man" J. Formosan Med. Assoc., 90, 437-442 (citations: 3)
221. W.-R. Shieh, D.-M. Gou, and C.-S. Chen (1991) "Computer-aided substrate design for
biocatalysis: An enzymatic access to optically active propranolol" J. Chem. Soc. Chem. Commun.
pp651-653 (citations: 4)
1990
222. C.-S. Chen, D. Copeland, S. Harriman, and Y.-C. Liu (1990) "Preparation of enantiomericallyactive deuterium-labelled ibuprofen" J. Labelled Compds & Radiopharmaceuticals, 28, 1017-1024
(citations: 2)
223. C.-S. Chen, Y.-C. Liu, and M. Marsella (1990) "A convenient chemoenzymatic synthesis of (R)and (S)-(Chloromethyl)oxirane" J. Chem. Soc. Perkin Trans. 1 pp2559-2561 (citations: 16)
224. Z.-W. Guo, S.-H. Wu, C.-S. Chen, G. Girdaukas, and C. J. Sih (1990) "Sequential biocatalytic
kinetic resolutions" J. Am. Chem. Soc., 112, 4942-4945 (citations: 65)
225. C.-S. Chen, T. Chen, and W.-R. Shieh (1990) "Metabolic stereoisomeric inversion of 2arylpropionic acids, On the mechanism of ibuprofen epimerization in rats" Biochim. Biophys. Acta,
1033, 1-6 (citations: 39)
1989
226. C.-S. Chen, and C. J. Sih (1989) "General aspects and optimization of enantioselective biocatalysis
in organic solvents: The use of lipases" Angew. Chem. Int. Ed. Engl., 28, 695-707 (citations: 656)
227. C.-S. Chen, and Y.-C. Liu (1989) "A chemoenzymatic access to optically active 1,2-epoxides"
Tetrahedron Lett., 30, 7165-7168 (citations: 25)
228. Y.-C. Liu, and C.-S. Chen (1989) "An efficient synthesis of optically active D-myo-inositol 1,4,5
triphosphate" Tetrahedron Lett., 30, 1617-1620 (citations: 52)
25
C.-S. Chen
1987
229. C.-S. Chen, Wu, S.-H., Girdaukas, G., and C. J. Shih (1987) "Quantitative analyses of biochemical
kinetic resolution of enantiomers. II. Enzyme-catalyzed esterifications in water-organic solvent
biphasic systems" J. Am. Chem. Soc., 109, 2812-2817 (citations: 318)
1986
230. C. J. Shih, W.-R. Shieh, C.-S. Chen,, S.-H. Wu, and G. Girdaukas. (1986) "Biochemical
asymmetric catalysis" Ann. New York Aca. Sci., 471, 239-254 (citations: 5)
231. Q.-M. Gu, C.-S. Chen, and C. J. Sih (1986) "A facile enzymatic resolution process for the
preparation of (+)-S-2-(6-methoxy-2-naphthyl)propionic acid (Naproxen)" Tetrahedron Lett., 27,
1763-1766 (citations: 130)
1985
232. Y.-F. Wang, C.-S. Chen, G. Girdaukas, and C. J. Sih (1985) "Extending the applicability of
esterases of low enantioselectivity in asymmetric synthesis" in "Enzymes in organic synthesis"
Battersby, A.R., ed., Pitman, London. (citations: 9)
233. S.-H. Wu, L.Q. Zhang, C.-S. Chen, G. Girdaukas, and C. J. Sih (1985) "Bifunctional chiral
synthons via biochemical methods. 7. Optically active 2,2'-dihydroxy-1,1'-binaphthyl" Tetrahedron
Lett., 26, 4323-4326 (citations: 42)
234. Y. F. Yang, C.-S. Chen, G. Girdaukas, C. J. Sih (1985) "Extending the applicability of esterases of
enantioselectivity in asymmntric-synthesis” Ciba Foundation Symposia, 111,128-145 (citations:9)
1984
235. C.-S. Chen, B.N. Zhou, W.-R. Shieh, F. VanMiddlesworth, A.S. Gopala,, and C. J. Sih (1984)
"Stereochemical control of yeast reductions. 2. Quantitative treatment of the kinetics of competing
enzyme system for a single substrate" Bioorg. Chem., 12, 98-117 (citations: 54)
236. Y. F. Wang, , C.-S. Chen, G. Girdaukas, and C. J. Sih (1984) "Bifunctional chiral synthons via
biochemical methods. 3. Optical purity enhancement in enzymic asymmetric catalysis" J. Am.
Chem. Soc., 106, 3695-3696 (citations: 146)
237. C. J. Sih, and C.-S. Chen. (1984) "Microbial asymmetric catalysis - Enantioselective reduction of
ketones" Angew. Chem. Int. Ed. Engl., 23, 570-578 (citations: 224)
238. C. J. Sih., B.N. Zhou, A.S. Gopalan, W.-R. Shieh, C.-S. Chen, Girdaukas, G., and
VanMiddlesworth, F. (1984) "Enantioselective reduction of -keto esters by bakers' yeast" Ann.
New York Aca. Sci., 434, 186-193 (citations: 9)
1982
239. C.-S. Chen, Y. Fujimoto, G. Girdaukas, C. J. Sih (1982) "Quantitative analyses of biochemical
kinetic resolutions of enantiomers" J. Am. Chem. Soc., 104, 7294-7299 (citations: 2,252)
240. Y. Fujimoto, C.-S. Chen, Z. Szelecky, D. DiTullio, and C. J. Sih (1982) "Microbial degradation of
the phytosterol side chain. 1. Enzymatic conversion of 3-oxo-24-ethyl-cholest-4-en-26-oic acid into
3-oxochol-4-en-24-oic acid and androst-4-ene-3,17-dione" J. Am. Chem. Soc., 104, 4718-4720
(citations: 35)
241. Y. Fujimoto, C.-S. Chen, A. S. Gopalan, and C. J. Sih (1982) "Microbial degradation of the
phytosterol side chain. 2. Incorporation of NaHC-14O3 onto the C-28 position" J. Am. Chem. Soc.,
104, 4720-4722 (citations: 23)
242. C.-S. Chen, S. H. Wu, and K. T. Wang (1982) "Determination of esterase activity of papain by
high performance liquid chromatography" J. Chromatogr., 248, 451-455 (citations: 3)
243. C. J. Sih, C.-S. Chen, G. Girdaukas, and B. N. Zhou (1982) "Design and synthesis of optically pure
compounds using microbial systems" in "The biology basis of new developments in biotechnology"
26
C.-S. Chen
Hollaender, A., Laskin, A., and Roger, P., eds., Plenum Press, N.Y.
1981
244. C.-S. Chen, Y. Fujimoto, and C. J. Sih (1981) "Bifunctional Chiral Synthons via Microbiological
Methods. 1. Optically active 2,4-dimethylglutaric acid monomethyl esters." J. Am. Chem. Soc.,
103, 3580-3582 (citations: 72)
VIII. Licenses, Awarded Patents and Patent Applications
A. Licenses
The PDK-1 inhibitor OSU-03012 (AR12) and the HDAC inhibitors OSU-HDAC42 (AR42) have been
licensed to Arno Therapeutics for clinical development.
B. Granted US Patents
Patent Number
Title
US 8,445,483
Anti-infective agents against intracellular pathogens
1
US 8,383,656
Thiazolidinedione energy restriction-mimetic agents
2
US 8,377,948
Antitumor agents and methods of their use
3
US 8,362,071
Antiadhesion agents
4
US 8,318,812
Therapeutic agents for the treatment of lymphoid malignancies
5
Zn2+chelating motif-tethered short-chain fatty acids as a novel class of
US 8,318,808
6
histone deacetylase inhibitors
US 8,309,768
FTY720-derived anticancer agents
7
US 8,309,582
Small molecule Bcl-Xl/Bcl-2 binding inhibitors
8
Alkyl indole-3-carbinol-derived antitumor agents
US 8,153,680
9
10
11
12
13
14
15
16
17
US 8,080,574
US 8,039,502
US 7,973,062
US 7,807,705
US 7,714,005
US 7,576,116
US 7,566,787
US 7,026,346
18
US 6,068,986
19
US 6,020,174
20
US 5,798,447
21
US 5,393,912
22
US 5,334,534
23
US 5,260,472
PDK-1/Akt signaling inhibitors
Anti-infective agents against intracellular pathogens
Androgen receptor-ablative agents
Potent indole-3-carbinol-derived antitumor agents
Small molecule Bcl-xL/Bcl-2 binding inhibitors
PDK-1/Akt signaling inhibitors
Small molecule cyclin D1 ablative agents
Compounds and methods for inducing apoptosis in proliferating cells
Antibodies specific for D-myo-inositol 1,4,5-trisphosphate and the enzymelinked immunosorbent assay of D-myo-inositol 1,4,5-trisphosphate
Chemoenzymatic synthesis of the taxol C-13 side chain N-benzolyl- (2R,3S)Phenylisoserine
Antibodies specific for D-myo-inositol 1, 4, 5-trisphosphate and the enzymelinked immunosorbent assay of D-myo-inositol 1, 4, 5-trisphosphate
D-myo-inositol 1,4,5-trisphosphate analogues
Enzymatic preparation of optically active propanolol and beta-adrenergic
blockers using esterase
Efficient chemoenzymatic synthesis of D-myo-inositol 1,4,5-triphosphate, Dmyo-inositol 1,3,4-triphosphate, and D-myo-inositol 1,3,4,5-tetraphosphate
27
C.-S. Chen
C. Pending US Patent Applications
Publication number
Title
1 US 2012/0108823 Al Anti-Francisella agents
PCT/US2011/57591 Anti-staphylococcal celecoxib derivatives
2
PCT/US2011/065754 DNA methylation inhibitors
3
IX. Grants (active)
1 R01 CA172576 (PI: Chen)
Agency: NCI; 3/1/2014 – 2/28/2019
Title: Translating Novel Antitumor Targets of Vitamin E into New Chemopreventive Agents
Based on the PI’s novel finding that vitamin E promotes Ser473-Akt phosphorylation in PTENdeficient cancer cells by facilitating PH domain-mediated membrane colocalization of Akt and
PHLPP1, this project is aimed at developing a novel class of PHLPP1-targeted Akt inhibitors for cancer
prevention.
5 R01 CA112250-09 (PI: Chen)
Agency: NCI; 12/1/2004 - 11/30/2015
Title: Novel energy restriction-mimetic agents for prostate cancer prevention
This proposal is aimed at testing the hypothesis that targeting tumor metabolism by novel glucose
transporter inhibitors has translational potential inprostate cancer prevention.
5 P50 CA140158-04 (PPG Leader: Byrd)
Agency: NCI; 8/17/2009 - 7/31/2015
SPORE - Experimental Therapeutics of Leukemia: Core D: Medicinal Chemistry
Role: Medicinal Chemistry Core Co-Director
LLS 7004-11 (SCOR Leader: Byrd)
Agency: Leukemia & Lymphoma Society; 10/1/2010 - 9/30/2015
Title: Experimental therapeutics in leukemia: Project 5 Molecular Target-Based Therapeutics for
Leukemia
Role: Project 5 Leader
Harrington Discovery Institute Scholar Innovator Award (PI: Schlesinger)
Agency: University Hospitals of Cleveland; 1/1/2013 – 12/31/2015
Title: Anti-TB drug discovery through lead optimization of protein kinase inhibitor OSU-03012
Role: Co-Investigator
The goal of this project is to identify new compounds that are effective against drug sensitive and
resistant strains of M. tuberculosis.
V. Lectures
2014
3.15.2014, Joint Symposium of Institute of Biomedical Sciences, Academia Sinica and Tzu Chi
University/Tzu Chi Hospital: Recent Advances in Biomedical Sciences
28
C.-S. Chen
“Integrin-Linked Kinase as a Molecular Switch of the IL-6-NF-kB Signaling Loop to Promote Breast
Cancer Stem Cell Phenotype”
2013
12.16.2013, Institute of Biological Chemistry, Academia Sinica, Taipei Taiwan
“Targeting phenotypic adaption of cancer cells to tumor microenvironment. Challenges and
opportunities”
6.10.2013, Plenary lecture, Mid-Atlantic Graduate Student Symposium in Medicinal Chemistry
“Molecular Target-Based Drug Discovery”
4.19. 2013, Graduate Institute of Biotechnology, National Kaohsiung University, Taiwan
“”How Vitamin E Prevents Cancer” a Novel Mechanism Targeting the Tumor Suppressor PHLPP1”
4.16.2013, College of Life Science, Kaohsiung Medical University, Kaohsiung, Taiwan
“Energy Metabolism as a Therapeutic Target for Drug Discovery”
4.4.2013, International Pancreatic Cancer Symposium, OSU
“Multi-Prong Strategy/Drug Discovery”
3.18.2013, 9th Annual National Symposium on Prostate Cancer, Clark Atlanta University, Atlanta
“Targeting Energy Metabolism in Prostate Cancer by Novel Agents”
2.28.2013, College of Pharmacy, University of Michigan, Ann Arbor, MI
“Therapeutic Development Targeting Tumor Microenvironment”
2.25.2013, Department of Veterinary Bioscience, OSU
“Therapeutic Development Targeting Tumor Metabolism”
1.11.13, National Cancer Research Institute, National Health Research Institutes, Tainan, Taiwan
“Targeting Tumor Metabolism and Microenvironment in Pancreatic Cancer”
2012
11.1.2012, Department of Medical Oncology, National Taiwan University Hospital, Taipei, Taiwan
“Therapeutic Development Targeting Tumor Microenvironment”
9.20.2012, University of Kentucky College of Pharmacy Annual Symposium on Drug Discovery &
Development, Lexington, KY
Keynote speech “Therapeutic Development Targeting Tumor Microenvironment”
7.6.2012, Taipei Medical University, Taipei, Taiwan
“Molecular Target-Based Drug Discovery. From Bench to the Clinic and Back”
7.7.2012, The 5th International Conference for the Treatment of Pancreatic Cancer, National Cheng Kung
University Hospital, Tainan, Taiwan
“Novel Therapeutic Development for Pancreatic Cancer”
5.17.2012, Graduate Institute of Molecular Biology, National Chung Hsing University, Taichung, Taiwan
“Novel Therapeutic Development Targeting Cancer Progression”
5.18.2012, 2012 International Symposium on Clinical and Translational Cancer Research, Kaohsiung,
Taiwan
Keynote speech “Therapeutic Development Targeting the IL-6-NF-kB Signaling Loop in Cancer Stem
Cells”
5.4.2012, OSUCCC Experimental Therapeutics Program Retreat
“Medicinal Chemistry Core Facility: Specific opportunities for Lead Optimization of Novel Therapeutic
Agents”
4.30.2012, Annual International Thyroid Oncology Group (ITOG) Conference, Biomedical Research
Tower, OSU
“Rational Drug Design for Progressive Solid Tumors”
2011
10.12.2011, NCKU-OSUCCC Mini-symposium on Pancreatic Cancer, National Cheng-KungUniversity,
29
C.-S. Chen
Taiwan
“Targeting Tumor Initiation, Metastatic Capacity, and Chemoresistance by Novel Therapeutic Agents”
10.11.2011, Institute of Biopharmaceutical Sciences, National Yang-Ming University, Taiwan
“Targeting Tumor Initiation, Metastatic Capacity, and Chemoresistance by Novel Therapeutic Agents”
8.15.2011, National Health Research Institute Biomedical Symposium, Taiwan
“Molecular Target-Based Drug Discovery. From Bench to the Clinic and Back”
8.12.2011, Institute of Molecular Biology, National Chung-Hsing University, Taiwan
“Targeting Tumor Initiation, Metastatic Capacity, and Chemoresistance by Novel Therapeutic Agents”
5.24.2011, 2nd Annual CCTS Scientific Meeting “Translational Therapeutics”, OSU
“Molecular Target-Based Drug Discovery. From Bench to the Clinic and Back”
5.17.2011, National Cheng-Kung University, College of Medicine, Taiwan
“Molecular target-Based Drug Discovery, From Bench to the Clinic”
5.16.2011, Division of Biotechnology and Pharmaceutical Development, National Health Research
Institutes, Taiwan
“PI3K Kinase Signaling, Epigenetics, and Tumor Metabolism. The Three Prongs in Anticancer Drug
Discovery”
3.12.2011, CDMRP Prostate Cancer Research Program 2011 IMPaCT (Innovative Minds in Prostate
Cancer Today) meeting, Orlando Florida
Therapeutics Plenary Lecture “Kinase Signaling, Epigenetics, and Tumor Metabolism. The Three Prongs
in Anticancer Drug Discovery”
2010
11.7. 2010, NCI Conference on AR Signaling, Washington DC
Section 3: Preclinical Models of AR Action Models for Drug Discovery
Targeting AR and IGF-1R/PI3K/Akt signaling in prostate cancer by novel energy restriction-mimetic
agents
11.2.2011, Departments of Pathology, The Johns Hopkins Medical Institutions
“PI3K Kinase Signaling, Epigenetics, and Tumor Metabolism. The Three Prongs in Anticancer Drug
Discovery”
6.21.2010, Department of Clinical Laboratory Sciences and Medical Technology, National Taiwan
University College of Medicine
“Kinase Signaling, Epigenetics, and Tumor Metabolism. The Three Prongs in Anticancer Drug
Discovery”
6.17.2010, Workshop on University-Based Cancer Drug Discovery and Development – OSUCCC
Experimental Therapeutics Program
“Design and Development of New Anti-Cancer Therapies”
5.28-29.2010, 3rd Annual Cancer Drug Discovery Symposium – Sudbury Regional Hospital, Sudbury,
Ontario, Canada
Keynote lecture “Kinase Signaling, Epigenetics, and Tumor Metabolism. The Three Prongs in
Anticancer Drug Discovery”
4.16.2010, Fu-Jen Catholic University College of Medicine Distinguished Lecture
“Development and Clinical Translation of Targeted Therapeutic Agents”
2.2-5.2010, 7th International Symposium for Chinese Medicinal Chemists, Kaohsiung, Taiwan
Keynote lecture “Target-Based Anticancer Drug Discovery”
2.1.2010, Development Center for Biotechnology, Taipei, Taiwan
“Kinases, Epigenetics, and Tumor Metabolism. The Three Prongs in Anticancer Drug Discovery”
30
C.-S. Chen
2009
11.10.2009, National Cheng-Kung University Graduate Institute of Biochemistry
“PI3K Kinase Signaling, Epigenetics, and Tumor Metabolism. The Three Prongs in Anticancer Drug
Discovery”
10.3.2009, Peking University College of Pharmacy
“Development and Clinical Translation of Targeted Therapeutic Agents”
10.22.2009, Zhejiang University
“Target-Based Anticancer Drug Discovery”
10.21.2009, Suzhou University College of Pharmacy
“Target-Based Anticancer Drug Discovery”
9.15.2009, Chemical Biology Interface Training Program, OSU
“PI3K Kinase Signaling, Epigenetics, and Tumor Metabolism. The Three Prongs in Anticancer Drug
Discovery”
6.26.2009, National Sun Yat-Sen University, Taiwan
“Targeting Epigenetics and Energy Metabolism in Cancer Therapy”
4.22.2009, AACR 2009 Annual Meeting
Co-chairman of the mini-symposium “Progress and Insights in Combination Chemotherapy”
2008
12.5.2008, Genomic Research Institute, Academia Sinica, Taiwan
“PI3K Kinase Signaling, Epigenetics, and Tumor Metabolism. The Three Prongs in Anticancer Drug
Discovery”
11.22.2008, Annual Meeting of Society of Basic Urological Research, Phoenix, AZ
“Prostate Cancer Prevention by a Novel Histone Deacetylase Inhibitor”
11.8.2008, NCI Translational Science Meeting
“Potent Indole-3-Carbinol-Derived Antitumor Agent with Pleiotropic Effects on Multiple Signaling
Pathways”
11.4.2008, University of Minnesota Cancer Center
“Molecular Target-Based Drug Discovery. From Bench to the Clinic”
6.20-22.2008, International Symposium on Cancer Clinical Trials and Drug Discovery, National ChengKung University Hospital, Taiwan
“Drug Discovery Research in Academia Institutions. An OSU Experience”
1.15.2008, NCI Clinical Development of Small Molecules Workshop
“Preclinical Development of OSU-03012 and OSU-HDAC42”
2007
10.5.2007, Chinese Medicine Functional Genomics Workshop, Taipei Medical University, Taiwan
Keynote lecture “Natural Products as Molecular Platforms for Developing Targeted Therapeutic
Agents”
9.6.2007, CDMRP PCRP IMPaCT Meeting, Atlanta, GA
“Molecular Target-Based Drug Discovery for Prostate Cancer”
3.14.2007, Mini-symposium in Chemical Biology, National Taiwan University-Academia Sinica
“Molecular Target-Based Anticancer Drug Discovery. From Bench to the Clinic”
2006
9.18.2006, University of Southern California School of Medicine
“Molecular Target-Based Anticancer Drug Discovery. From Bench to the Clinic”
31
C.-S. Chen
7.20, 2006, Indiana University School of Medicine
“Targeting Epigenetics and Intracellular Signaling in Cancer Therapy”
4.5.2006, ASPET symposium "Therapeutics and Toxicology of COX-2 inhibitors" San Francisco
“Non-COX-2 inhibitor analogs and the pathways inhibited; relationship to cancer therapy
2005
12.12-13.2005, International Symposium on Phytochemicals: Bioactives, Genomics, and Proteomics.
National Chiayi University, Taiwan
Keynoter lecture “Molecular Target-Based Anticancer Drug Discovery. From Bench to the Clinic”
12.2-6.2005, International Symposium on New Drug Development. From Bench to Clinic. Taipei,
Taiwan
“Targeting Epigenetics and Intracellular Signaling in Cancer Therapy”
11.9.2005, Annual Meeting of Society of Basic Urological Research, Savannah, Georgia
“Targeting PI3K/Akt signaling in Prostate Cancer Therapy”
10.5.2005, Weis Medical Center, Harrisburg, PA
“Molecular Target-Based Anticancer Drug Discovery. From Bench to the Clinic”
9.16.2005, Department of Chemical Biology, Rutgers University, Piscataway, NJ
“Molecular Target-Based Anticancer Drug Discovery. From Bench to the Clinic”
8.17.2005, Roswell Park Research Institute
“Development of Molecular Target-Based Anticancer Agents. From Discovery to the Bedside”
7.29, 2005, Prostate Cancer SPORE Ground rounds seminar, Mayo Clinic
“A Targeted, Combinatorial Approach to Prostate Cancer Therapy”
2004
12.7.2004, Annual Congress of the Pharmaceutical Society, Taiwan
Plenary Lecture “Development of Molecular Target-Based Anticancer Agents. From Discovery
to the Bedside”
10.19.2004, Department of Pharmaceutical Sciences, Medical University of South Carolina
“Molecular Target-Based Cancer Therapy”
10.4.2004, Department of Molecular and Cellular Biochemistry, University of Nebraska
“Targeting PI3K/Akt Signaling in Cancer Therapy. Challenges and Opportunities”
9.7.2004, City of Hope Comprehensive Cancer Center
“Molecular Target-Based Caner Therapy”
9.1.2004, Human Cancer Genetics, OSUCCC
“Targeting PI3K/Akt Signaling in Cancer Therapy. Challenges and Opportunities”
5.19.2004, University of Kentucky Medical Center
“Molecular Target-Based Caner Therapy”
2003
12.11.2003, College of Pharmacy, Kao-Hsiung Medical University, Taiwan
“Targeting Akt Signaling in Cancer Therapy – Challenges and Opportunities”
12.9.2003, Chang-Gung University
“Targeting Akt Signaling in Cancer Therapy – Challenges and Opportunities”
12.7.2003, Chinese Pharmaceutical Society 50th anniversary meeting, Taiwan
Plenary Lecture “Molecularly Targeted Drug Design”
32
C.-S. Chen
11.5.2003, College of Pharmacy, University of North Carolina-Chapel Hill
“Molecularly Targeted Anticancer Agents”
10.3.2003, OSUCCC Grand Rounds
“Targeting PI3K/Akt Signaling in Cancer Therapy. Challenges and Opportunities”
8.27.2003, Therapeutics Development Program, NCI/NIH
“Akt-targeted Agents as Novel Therapeutic Agents”
7.6-11.2003, Gordon Conference on Hormonal Carcinogenesis; Kimball Union Academy, NH
“Targeting PDK-1/Akt Signaling in Prostate Cancer”
2.28.2003, Laboratory of Biosystem & Cancer, Center for Cancer Research, NCI/NIH
“From Celecoxib to a Novel Class of Molecularly Targeted Anti-Tumor Agents”
2002
9.26.2002, College of Pharmacy, University of Arizona
“New Drug Development for Prostate Cancer – Targeting PDK-1/Akt Signaling”
9.2.2002, Fifth International Congress on Essential Fatty Acids and Eicosanoids; Taipei, Taiwan
“COX-2 in Cancer, A Role yet to be Defined”
2001
11.20.2001, Chemistry & Biology Interface Training Program, OSU
“PI3-Kinase Signaling. Mechanism and Novel Function”
10.16.2001, Department of Pharmacology, OSU
“Novel Function of PI 3-Kinase in Receptor-Mediated Ca2+ Signaling”
9.25.2001, OSUCCC Prostate Cancer Research Group
“Apoptosis Regulation by COX-2 Inhibitors in Prostate Cancer Cells”
9.18.2001, Chemistry & Biology Interface Training Program. OSU
“Apoptosis Regulation by Lipid Signals in Prostate Cancer”
7.9.2001, Graduate Institute of Biomedical Sciences, National Sun Yat-Sen University, Taiwan
“ApoptosisRegulation by Lipid Signals in Prostate Cancer”
5.20.2001, Ohio State Biochemistry Program, OSU
“PI 3-Kinase Signaling. Mechanism and Novel Function”
4.25.2001, Department of Medicinal & Natural Products Chemistry, University of Iowa
“Apoptosis Regulation by COX-2 Inhibitors in Prostate Cancer”
2000 and before
12.5.2000, Hormones and Cancer Group, OSU Comprehensive Cancer Center
“New Drug Development for Prostate Cancer”
12.13.2000, Kaohsiung Medical University, Taiwan
“New Drug Design for Prostate Cancer”
11.11.2000, Rennebohm Seminar Series, University of Wisconsin, Madison
“New Drug Design for Prostate Cancer”
11.6.2000, Ground Rounds, Department of Pathology, University of Rochester
“COX-2 Inhibitors as Apoptosis-Inducing Agents in Prostate Cancer”
10.2.2000, Forty-first International Symposium on Regulation of Enzyme Activity and Synthesis in
Normal and Neoplastic Tissues, Indianapolis, IN
“Apoptosis Signaling Pathways Mediated by Cyclooxygenase-2 Inhibitors in Prostate Cancer Cells”
5.1.2000, Grand Round, Department of Pathology, University of Texas Medical Branch, Galveston, TX
33
C.-S. Chen
“Apoptosis Regulation by COX-2 Inhibitors in Prostate Cancer Cells”
1.19.2000, Division of Medicinal Chemistry, College of Pharmacy, OSU
“Regulation of Apoptosis by Lipid Signals in Prostate Cancer Cells”
10.18.1999, Institute of Biological Sciences, Academia Sinica, Taiwan
“Regulation of Apoptosis by COX-2 Inhibitors in Cancer Cells”
5.3.1999, Loeb Health Research Institute, University of Ottawa, Canada
“PI 3-Kinase, Calcium Regulation, and Apoptosis”
3.18.1999, Apoptosis Interest Group, Combs Cancer Center, University of Kentucky
“PI 3-Kinase as a Survival Factor in Cancer Cells”
3.2.1999, Schering Plough Research Institute; Tumor Biology Seminar
“Apoptosis Regulation in Prostate Cancer”
12.19.1998, Department of Pharmacology, College of Medicine, University of Kentucky
“PI 3-Kinase, Calcium Regulation, and Apoptosis”
10.29.1998, Advanced Science and Technology Commercialization Center, University of Kentucky
“Phosphoinositide 3-Kinase: A New Therapeutic Target”
8.23.1998, EMBO Workshop; Calcium Signals in the Cell Nucleus, Strasbourg, France
“Nuclear Calcium Regulation by Inositol Phosphates and Cyclic ADP-Ribose” & “Phosphoinositide
3-Kinase in Rat Liver Nuclei”
7.20-24.1998, The First International Symposium for Chinese Medicinal Chemists, Taiwan
“Phosphoinositide 3-Kinase Signaling and Its Implications as a Therapeutic Target”
3.6.1998, UT Southwestern Medical Center, University of Texas
“Molecular Targets of Phosphoinositide 3-Kinase Lipid Products”
8.24.1997, Department of Microbiol. & Immunol., College of Medicine, University of Kentucky
“Molecular Targets of Phosphoinositide 3-Kinase Lipid Products”
9.8-10.1997, 214th ACS National Meeting; Las Vegas; Symposium on “Advances in
Phosphoinositides”; September 8 -10, 1997; Co-organizer of the symposium
“On the Molecular Targets of Phosphoinositide 3-Kinase Lipid Products”
6.3.1996, Institute of Biomedical Sciences, Academia Sinica, Taipei, Taiwan
“Phosphoinositide-mediated signal transduction”
7.18.1995, XIIIth International Conference on Phosphorus Chemistry, Jerusalem, Israel
“Modulation of the inositol 1,4,5-trisphosphate receptor by inositol phosphates”
1.23.1995, Department of Pharmacy, College of Medicine, National Taiwan University, Taiwan
“Regulation of Intracellular Calcium by Inositol Phosphates”
10.20.1994, DuPont-New England Nuclear, Boston
“Chemistry and Biochemistry of Inositol Phosphates”
9.8.1994, College of Pharmacy, State University of New York at Buffalo
“Stereoselective Recognition in Biological Systems”
8.11.1994, Central Research Division, Pfizer Inc.
“Asymmetric Biocatalysis in Organic Synthesis”
6.6.1994, College of Pharmacy, University of Kentucky
“Stereoselective Recognition in Biological Systems”
8.24.1993, Institute of Chemistry, Academia Sinica, Taipei, Taiwan
“Enantioselective Drug Metabolism” and “Asymmetric Biocatalysis in Organic Synthesis”
10.26.1992, College of Pharmacy, University of Connecticut
“Chiral Recognition in Biochemical Catalysis”
34
C.-S. Chen
6.11-12.1992, College of Pharmacy, Toho University, Chiba, Japan
“Enantioselective Drug Metabolism” & “Asymmetric Biocatalysis in Organic Synthesis”
5.12.1992, American Oil Chemists' Society Annual Meeting, Toronto, Canada
“Enantioselectivity Improvement in Biocatalytic Resolutions”
6.5.1991, Institute of Biochemical Sciences, Academia Sinica, Taipei, Taiwan
Workshop on "Asymmetric Biocatalysis in Chemical Synthesis"
4.6.1990, Department of Chemistry, University of Rhode Island
“Chirality Implications in Biochemical Catalysis: Stereoselective Drug Metabolism and Enzymatic
Asymmetric Synthesis”
4.11.1989, Department of Chemistry, Brown University
“Asymmetric Catalysis by Lipases: Basic Principles and Applications”
12.7.1987, Department of Chemistry, Iowa State University
“Enzymes as Chiral Catalysts in Organic Synthesis”
35